var title_f34_15_35056="Azithromycin: Pediatric drug information";
var content_f34_15_35056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azithromycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/2/10275?source=see_link\">",
"       Azithromycin (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/3/6200?source=see_link\">",
"       Azithromycin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12937 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35056=[""].join("\n");
var outline_f34_15_35056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/2/10275?source=related_link\">",
"      Azithromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/3/6200?source=related_link\">",
"      Azithromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_15_35057="Balantis xerotica obliterans";
var content_f34_15_35057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balantis xerotica obliterans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These photographs depict three foreskins with the classic appearance of balanitis xerotica obliterans. The phimotic ring is closed, but the indurated, white scar is readily discernible from normal, healthy skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Metcalfe PD, Elyas R. Foreskin management: Survey of Canadian pediatric urologists. Can Fam Physician 2010; 56:e290. Copyright &copy; 2010 Canadian Family Physician.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35057=[""].join("\n");
var outline_f34_15_35057=null;
var title_f34_15_35058="Disseminated cryptococcosis - papules";
var content_f34_15_35058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated cryptococcosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple umbilicated papules are present on the face of this patient with cryptococcosis. The lesions resemble molluscum contagiosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35058=[""].join("\n");
var outline_f34_15_35058=null;
var title_f34_15_35059="Microbiology specimen collection and transport";
var content_f34_15_35059=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology specimen collection and transport",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35059/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35059/contributors\">",
"     Susan E Boruchoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35059/contributors\">",
"     Melvin P Weinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35059/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35059/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35059/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35059/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/15/35059/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of microbiologic evaluation is to provide accurate, clinically pertinent results in a timely manner. The quality of the specimens submitted to the microbiology laboratory is critical for optimal specimen evaluation.",
"   </p>",
"   <p>",
"    The general techniques of specimen collection and handling that have been established both to maximize the yield of organisms and isolate relevant pathogens from specimens obtained from different body sites will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef78605 graphicRef54592 graphicRef67280 graphicRef82682 \" href=\"mobipreview.htm?13/58/14255\">",
"     table 1A-D",
"    </a>",
"    ). The techniques of collecting specific specimens such as blood, sputum, and urine are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11494?source=see_link\">",
"     \"Blood cultures for the detection of bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=see_link\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=see_link\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPECIMEN COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valid interpretation of the results of culture can be achieved only if the specimen obtained is appropriate for processing. As a result, care must be taken to collect only those specimens that may yield pathogens, rather than colonizing flora or contaminants. Specific rules for the collection of material vary, depending upon the source of the specimen, but several general principles apply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35059/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Make every effort to obtain specimens prior to the initiation of antimicrobial therapy.",
"     </li>",
"     <li>",
"      Wear gloves, gowns, masks,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      goggles, when appropriate, when collecting specimens from sterile sites. Use strict aseptic technique.",
"     </li>",
"     <li>",
"      When obtaining specimens from normally sterile sites such as pleural or joint spaces, CSF, or the peritoneum, take care to minimize contamination by the normal colonizing flora of the skin or mucous membranes.",
"     </li>",
"     <li>",
"      Collect an adequate volume of specimen; send tissue or fluid whenever possible rather than submitting a specimen collected on a swab.",
"     </li>",
"     <li>",
"      If the specimen is collected in a syringe, remove the needle and replace it with a cap prior to transport.",
"     </li>",
"     <li>",
"      Label all specimen containers with identifying information about the patient (name and hospital number or birth date) and the specimen source and date and time of collection.",
"     </li>",
"     <li>",
"      Complete all paper or electronic requisitions completely and precisely, including requested details on patient history, antimicrobial therapy, and specimen source, so that the laboratory can best determine the appropriate method for processing the specimen.",
"     </li>",
"     <li>",
"      Notify the laboratory in advance if special tests are requested or if unusual pathogens, including potential agents of bioterrorism, are suspected.",
"     </li>",
"     <li>",
"      Place warning labels on specimens from patients suspected of having highly contagious diseases and notify the laboratory supervisor.",
"     </li>",
"     <li>",
"      Coordinate the processing of specimens which are being submitted for both microbiologic and pathologic evaluations. It is often better to send a single specimen to the laboratory, and to have it divided there by an experienced pathologist, rather than submitting separate specimens. If a single sample is submitted, it must not be placed in the preservatives routinely used for pathology specimens (eg, formalin) until a portion is separated for culture.",
"     </li>",
"     <li>",
"      If there is any question about the optimal sample to collect, call the microbiology laboratory before obtaining specimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIMEN TRANSPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, specimens may be sent to the microbiology laboratory in sterile, leakproof containers enclosed within leakproof, sealed plastic bags. In the case of fluids obtained in syringes (eg, paracentesis, joint aspirate, needle drainage of abscess), most organisms remain viable for significant periods of time in the syringe used for collection. It has long been advocated that these specimens be sent in the original syringe. However, in the era of universal precautions, some laboratories encourage transfer of the material to another container prior to transport, while others recommend transport in the original syringe after the needle is removed and replaced with a cap. In our institution, the microbiology laboratory prefers to receive specimens in the original syringe, as long as the needle has been replaced with a cap. The laboratory will also accept specimens in other containers but will reject any syringe that arrives with the needle still in place.",
"   </p>",
"   <p>",
"    Prompt transport of specimens to the microbiology laboratory is essential in order to optimize the yield of cultures and the interpretation of results. Delays in processing may result in the overgrowth of some microorganisms or the death of more fastidious ones. Desiccation of the sample must also be avoided.",
"   </p>",
"   <p>",
"    Samples for bacterial culture should ideally arrive in the microbiology laboratory within one to two hours of collection. If a delay is unavoidable, most specimens (with the exception of blood, cerebrospinal fluid, joint fluid, and cultures for Neisseria gonorrhoeae) should be refrigerated until transported. It is important to add that refrigeration should occur in a refrigerator approved for specimen collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specimen rejection by the laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common reasons for rejection of specimens by microbiology laboratories include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unlabeled specimens",
"     </li>",
"     <li>",
"      Inconsistent information on the requisition and the specimen label (eg, different patient names)",
"     </li>",
"     <li>",
"      Specimen received in a leaking or broken container",
"     </li>",
"     <li>",
"      Specimen obviously contaminated",
"     </li>",
"     <li>",
"      Inappropriate test request based upon the source of the specimen (",
"      <a class=\"graphic graphic_table graphicRef78605 graphicRef54592 graphicRef67280 graphicRef82682 \" href=\"mobipreview.htm?13/58/14255\">",
"       table 1A-D",
"      </a>",
"      ) or clinical situation (eg, request for a stool culture for enteric pathogens in a patient hospitalized for more than three days)",
"     </li>",
"     <li>",
"      Inappropriate transport medium for the requested test (eg, anaerobic cultures requested for specimen submitted in aerobic transport media)",
"     </li>",
"     <li>",
"      Insufficient quantity of specimen",
"     </li>",
"     <li>",
"      Specimen transported at an inappropriate temperature",
"     </li>",
"     <li>",
"      Prolonged specimen transport time",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important that the microbiology laboratory notify the responsible physician promptly when a specimen is rejected, so that appropriate measures can be taken to obtain more material. If there is a labeling problem, the person responsible for collecting the specimen may be able to rectify the paperwork error. In situations in which obtaining another specimen is not feasible (eg, surgical or other invasive procedure required to obtain the original specimen), the laboratory may have to proceed with specimen processing, even though the validity of the results may be compromised. Such decisions typically are made in collaboration with the patient's physician, and laboratory reports usually are accompanied by a disclaimer.",
"   </p>",
"   <p>",
"    Examples of specimens which are unsuitable for culture include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35059/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Swabs of decubitus ulcer, perirectal abscess, periodontal lesion, burn wound, gangrenous ulcer &mdash; submit aspirate or tissue instead",
"     </li>",
"     <li>",
"      Vomitus",
"     </li>",
"     <li>",
"      Colostomy discharge",
"     </li>",
"     <li>",
"      Foley catheter tip",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13586396\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of microbiologic evaluation is to provide accurate, clinically pertinent results in a timely manner. The quality of the specimens submitted to the microbiology laboratory is critical for optimal specimen evaluation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Valid interpretation of the results of culture can be achieved only if the specimen obtained is appropriate for processing. As a result, care must be taken to collect only those specimens that may yield pathogens, rather than colonizing flora or contaminants. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Specimen collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The requesting clinician can help to ensure that the specimens are processed appropriately by completing requisitions accurately and by providing the laboratory with as much relevant information as possible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Specimen collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, specimens may be sent to the microbiology laboratory in sterile, leakproof containers enclosed within leakproof, sealed plastic bags. Prompt transport of specimens to the microbiology laboratory is essential in order to optimize the yield of cultures and the interpretation of results. Delays in processing may result in the overgrowth of some microorganisms or the death of more fastidious ones. Desiccation of the sample must also be avoided. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Specimen transport'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35059/abstract/1\">",
"      Wilson ML. General principles of specimen collection and transport. Clin Infect Dis 1996; 22:766.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, JM, Krisher, K, Holmes, HT. General principles of specimen collection and handling. In: Manual of Clinical Microbiology, 9th ed, Murray, PR, Baron, EJ, Jorgensen, JH, et al (Eds), American Society for Microbiology, Washington 2007. p.43.",
"    </li>",
"    <li>",
"     Specimen Management. In: Bailey &amp; Scott's Diagnostic Microbiology, 12th ed, Forbes, BA, Sahm, DF, Weissfeld, AS (Eds), Mosby, Elsevier, St. Louis, 2007. p 62.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2743 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35059=[""].join("\n");
var outline_f34_15_35059=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13586396\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPECIMEN COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIMEN TRANSPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specimen rejection by the laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13586396\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2743\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2743|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/44/1741\" title=\"table 1A\">",
"      Specimen collection methods I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/44/27340\" title=\"table 1B\">",
"      Specimen collection methods II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/52/9037\" title=\"table 1C\">",
"      Specimen collection methods III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/51/13116\" title=\"table 1D\">",
"      Specimen collection methods IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_15_35060="Roflumilast: Drug information";
var content_f34_15_35060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Roflumilast: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/11/43188?source=see_link\">",
"    see \"Roflumilast: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12918639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Daliresp&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11450895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Daxas&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11460288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase-4 Enzyme Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11460378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      COPD:",
"     </b>",
"     Oral: 500 mcg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11460379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11460380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11460381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment is recommended. Use with caution; 500 mcg once daily dose has not been evaluated in mild impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate-to-severe impairment (Child-Pugh class B or C): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12915805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daliresp&reg;: 500 mcg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11460409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Daxas&trade;: 500 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11460286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13727205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM286063.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM286063.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11460406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11460289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to bronchodilator therapy in the maintenance treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11460345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%), dizziness (2%), insomnia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Gastrointestinal: Diarrhea (10%), weight loss (8%; 7%: &gt;10% loss), nausea (5%), appetite decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal pain, anemia, arthralgia, arthritis, AST increased, atrial fibrillation depression, epistaxis, gastritis, GERD, GGT increased, gynecomastia, hematochezia, hypersensitivity, LDH increased, lung cancer, malaise, muscle spasm, muscle weakness, myalgia, pancreatitis, paresthesia, prostate cancer, rash, renal failure, respiratory tract infection, rhinitis, sinusitis, suicidal ideation/behavior, suicide completed, supraventricular arrhythmia, taste abnormal, tremor, urinary tract infection, urticaria, vertigo, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11460292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate or severe hepatic impairment (Child-Pugh class B or C)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindication (not in U.S. labeling): Hypersensitivity to roflumilast or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11460293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal effects: May cause weight loss and/or diarrhea (sometimes severe); weight loss usually observed within 6 months of initiating therapy and diarrhea within 4 weeks. Instruct patients to monitor weight regularly. Avoid initiation of therapy or discontinue therapy with unexplained/pronounced weight loss.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuropsychiatric: Neuropsychiatric effects (eg, anxiety, depression) have been reported with use; rarely, suicidal behavior/ideation and completed suicide were reported. Avoid use in patients with a history of depression with suicidal behavior/ideations; instruct patients/caregivers to report psychiatric symptoms and consider discontinuation of therapy in such patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Systemic exposure may be increased in patients with mild hepatic impairment; use in moderate-to-severe impairment is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not indicated for relieving acute bronchospasms or for use as monotherapy of COPD; use only as adjunctive therapy to bronchodilator therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Canadian labeling recommendations (not in U.S. labeling): Avoid use in patients with cancer (excluding basal cell carcinoma), heart failure (NYHA III/IV), severe acute infection, immunosuppression or immunosuppressive therapy (excludes short-term systemic corticosteroid use for COPD exacerbation), and patients &lt;18 years. Hypersensitivity reactions may occur following administration; monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11562394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase serum concentrations of the active metabolite(s) of Roflumilast. Cimetidine may increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Roflumilast. Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase serum concentrations of the active metabolite(s) of Roflumilast. FluvoxaMINE may increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Budesonide (Systemic, Oral Inhalation); Cytarabine (Liposomal); Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Roflumilast. Management: Roflumilast U.S. prescribing information recommends against combining rifampin with roflumilast.  The Canadian product monograph makes no such recommendation but notes that rifampin may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12911503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11460290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated reproductive toxicity (incomplete ossification, post-implantive losses) at doses greater than the human recommended dose. There are no adequate and well controlled studies in pregnant women. Avoid use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11460291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Roflumilast and/or its metabolites are excreted into the breast milk of lactating rats. Excretion into human breast milk is likely. Avoid use while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11460368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be given with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Daliresp Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg (90): $661.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11460408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests. Measure weight regularly during therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Daliresp (EE);",
"     </li>",
"     <li>",
"      Daxas (AR, CH, CZ, DE, DK, EE, FR, GB, HK, IE, KP, MY, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11460404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Roflumilast and its active N-oxide metabolite selectively inhibit phosphodiesterase-4 (PDE4) leading to an accumulation of cyclic AMP (cAMP) within inflammatory and structural cells important in the pathogenesis of COPD. Anti-inflammatory effects include suppression of cytokine release and inhibition of lung infiltration by neutrophils and other leukocytes. Pulmonary remodeling and mucociliary malfunction are also attenuated.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11460367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99%; N-oxide metabolite: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4 and CYP1A2 to active N-oxide metabolite; also undergoes conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 17 hours; N-oxide metabolite: 30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~1 hour (delayed by food); N-oxide metabolite: ~8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~70% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Calverley PM, Rabe KF, Goehring UM, et al, &ldquo;Roflumilast in Symptomatic Chronic Obstructive Pulmonary Disease: Two Randomised Clinical Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9691):685-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35060/abstract-text/19716960/pubmed\" id=\"19716960\" target=\"_blank\">",
"        19716960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chong J, Poole P, Leung B, et al, \"Phosphodiesterase 4 Inhibitors for Chronic Obstructive Pulmonary Disease,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2011, 5:CD002309.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35060/abstract-text/21563134/pubmed\" id=\"21563134\" target=\"_blank\">",
"        21563134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herbert C, Hettiaratchi A, Webb DC, et al, &ldquo;Suppression of Cytokine Expression by Roflumilast and Dexamethasone in a Model of Chronic Asthma,&rdquo;",
"      <i>",
"       Clin Exp Allergy",
"      </i>",
"      , 2008, 38(5):847-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35060/abstract-text/18307529/pubmed\" id=\"18307529\" target=\"_blank\">",
"        18307529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rennard SI, Calverley PM, Goehring UM, et al, \"Reduction of Exacerbations by the PDE4 Inhibitor Roflumilast -- The Importance of Defining Different Subsets of Patients With COPD,\"",
"      <i>",
"       Respir Res",
"      </i>",
"      , 2011, 12:18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35060/abstract-text/21272339/pubmed\" id=\"21272339\" target=\"_blank\">",
"        21272339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabatini F, Petecchia L, Boero S, et al, &ldquo;A Phosphodiesterase 4 Inhibitor, Roflumilast N-Oxide, Inhibits Human Lung Fibroblast Functions",
"      <i>",
"       in vitro",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Pulm Pharmacol Ther",
"      </i>",
"      , 2010, 23(4):283-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35060/abstract-text/20226872/pubmed\" id=\"20226872\" target=\"_blank\">",
"        20226872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MJ, Cortijo J, Taha MA, et al, &ldquo;Roflumilast Inhibits Leukocyte-Endothelial Cell Interactions, Expression of Adhesion Molecules and Microvascular Permeability,&rdquo;",
"      <i>",
"       Br J Pharmacol",
"      </i>",
"      , 2007, 152(4):481-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35060/abstract-text/17704822/pubmed\" id=\"17704822\" target=\"_blank\">",
"        17704822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16465 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35060=[""].join("\n");
var outline_f34_15_35060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12918639\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11450895\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460288\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460378\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460379\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460380\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460381\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12915805\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460409\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460286\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13727205\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460406\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460289\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460345\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460292\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460293\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300013\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562394\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911503\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460290\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460291\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460368\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322885\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460408\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276710\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460404\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460367\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16465|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/11/43188?source=related_link\">",
"      Roflumilast: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_15_35061="Biclonal gammopathy on SPEP";
var content_f34_15_35061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54186%7EHEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54186%7EHEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biclonal gammopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel B: A biclonal pattern, with two small, discrete gamma bands, is seen on serum protein electrophoresis on agarose gel (anode on left). Panel A: Densitometer tracing of these findings shows the two protein peaks with gamma mobility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Normal pattern on serum protein electrophoresis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Looking from left to right on the serum protein electrophoresis, a normal pattern has a large peak representing albumin followed by significantly smaller peaks for alfa-1, alfa-2, beta, and gamma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35061=[""].join("\n");
var outline_f34_15_35061=null;
var title_f34_15_35062="Vestibular neuritis";
var content_f34_15_35062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vestibular neuritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35062/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35062/contributors\">",
"     Joseph M Furman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35062/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35062/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35062/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35062/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/15/35062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular neuritis is also known as vestibular neuronitis, labyrinthitis, neurolabyrinthitis, and acute peripheral vestibulopathy. It is a benign disorder, self-limited, and associated with a complete recovery in most patients. Nonetheless, its symptoms of vertigo, nausea, vomiting, and gait impairment can be disabling in the short term.",
"   </p>",
"   <p>",
"    Vestibular neuritis also shares clinical features with less benign disorders, particularly acute vascular lesions of the central nervous system, from which it must be accurately differentiated in order to avoid morbidity and mortality.",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology, clinical manifestations, diagnosis, and treatment of vestibular neuritis. The evaluation and differential diagnosis of vertigo are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular neuritis is generally understood to be a viral or postviral inflammatory disorder affecting the vestibular portion of the eighth cranial nerve. This pathophysiological mechanism is not necessarily accurate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/1\">",
"     1",
"    </a>",
"    ]. There are little pathologic data to support this mechanism in patients with this disorder, and a history of a preceding viral illness is elicited in less than one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular neuritis, also known as vestibular neuronitis and labyrinthitis, represents an acute, spontaneous, peripheral vestibular ailment, characterized by the rapid onset of severe vertigo with nausea, vomiting, and gait instability.",
"   </p>",
"   <p>",
"    Physical examination findings are consistent with an acute vestibular imbalance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous vestibular nystagmus that is unilateral, horizontal, or horizontal-torsional, that is suppressed with visual fixation, and that does not change direction with gaze. The fast phase of nystagmus beats away from the affected side.",
"     </li>",
"     <li>",
"      Positive head thrust test. With rapid turning of the head toward the side of the lesion by the examiner, the patient is unable to maintain visual fixation. In one series, this was present in 82 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients in this series with a positive head thrust sign were also more likely to have persistent symptoms. While a positive head thrust test supports the diagnosis of vestibular neuritis, it does not definitively rule out a central nervous system disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link&amp;anchor=H22#H22\">",
"       \"Approach to the patient with vertigo\", section on 'Other vestibular signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gait instability with preserved ability to ambulate. If the patient sways or falls, it is opposite to the direction of the fast component of the nystagmus, ie, toward the affected side.",
"     </li>",
"     <li>",
"      Other neurologic signs and symptoms (dysarthria, dysphagia, weakness, sensory loss, facial droop, limb dysmetria) are absent. Vertical diplopia or skew eye deviation may be present due to an imbalance in otolithic-ocular reflexes, although its presence suggests that the patient has had a stroke. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link&amp;anchor=H22#H22\">",
"       \"Approach to the patient with vertigo\", section on 'Other vestibular signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In pure vestibular neuritis, auditory function is preserved; when this syndrome is combined with unilateral hearing loss, it is called labyrinthitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study of 101 patients, three clinical signs, in particular, were useful in distinguishing vestibular neuritis from a cerebrovascular event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/7\">",
"     7",
"    </a>",
"    ]. The presence of either a normal head thrust test, a skew deviation, or direction changing nystagmus had a 100 percent sensitivity and a 96 percent specificity for stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many conditions cause vertigo (",
"    <a class=\"graphic graphic_table graphicRef66539 \" href=\"mobipreview.htm?24/29/25051\">",
"     table 1",
"    </a>",
"    ). The clinical features of common causes of vertigo are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef81596 \" href=\"mobipreview.htm?9/14/9453\">",
"     table 2",
"    </a>",
"    ). The differential diagnosis of vertigo is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principal differential diagnostic concern in a patient presenting with acute sustained vertigo is a vascular event in the central nervous system affecting the cerebellum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brainstem. This possibility should be considered in all patients with vascular risk factors, because of the relatively high risk of recurrent vascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cerebellar hemorrhage or infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important consideration in the differential diagnosis of a patient with acute sustained vertigo is a vascular event (infarction or hemorrhage) in the cerebellum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/9\">",
"     9",
"    </a>",
"    ]. As many as 25 percent of patients older than 50 years presenting to the emergency department with this clinical picture have a cerebellar infarction rather than vestibular neuritis, although the percentage is usually reported as much lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As this alternative diagnosis represents a potentially immediately life-threatening condition, it is important to consider this possibility in every patient who presents with acute sustained vertigo. Patients with acute cerebellar lesions may have distinctive clinical features from that of vestibular neuritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nystagmus is not suppressed with visual fixation. It may be other than horizontal or horizontal-torsional, and may change direction with gaze.",
"     </li>",
"     <li>",
"      Patients are usually unable to stand or walk unsupported. The direction of falling is not necessarily opposite to the direction of the nystagmus.",
"     </li>",
"     <li>",
"      There may also be limb dysmetria, dysarthria, or headache.",
"     </li>",
"     <li>",
"      Head thrust test is usually normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a vascular event are typically older",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have atherosclerosis risk factors (hypertension, diabetes, smoking).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these caveats, the distinction between vestibular neuritis and acute cerebellar lesions is not always apparent; patients with acute vertigo are often quite ill, and the examination may be limited. When the diagnosis is unclear, a neuroimaging study may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Brainstem infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common stroke syndrome producing vertigo is a lateral medullary infarction producing a constellation of symptoms and signs known as a Wallenberg syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ipsilateral Horner's syndrome",
"     </li>",
"     <li>",
"      Dissociated sensory loss (loss of pain and temperature sensation on the ipsilateral face and contralateral limbs and trunk)",
"     </li>",
"     <li>",
"      Abnormal eye movements",
"     </li>",
"     <li>",
"      Ipsilateral loss of corneal reflex",
"     </li>",
"     <li>",
"      Hoarseness and dysphagia",
"     </li>",
"     <li>",
"      Ipsilateral limb ataxia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these signs are usually apparent after a careful neurologic examination, these signs may be overlooked by patients and nonneurologists because the vertigo, nausea, and vomiting may overwhelm the clinical pictures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=see_link&amp;anchor=H8#H8\">",
"     \"Posterior circulation cerebrovascular syndromes\", section on 'Lateral medullary infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More restrictive brainstem infarctions have been described that affect isolated vestibular structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, their clinical manifestations are very similar to vestibular neuritis. While accurate diagnosis is still desirable, there is somewhat less clinical imperative to diagnose these lesions, especially urgently. These are usually due to small arterial disease related to age, hypertension, and diabetes. The long-term management for this condition is atherosclerosis risk factor management and antiplatelet therapy, which are both indicated even in the absence of a known cerebrovascular event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of vestibular neuritis is largely based on clinical information. There are no specific diagnostic tests.",
"   </p>",
"   <p>",
"    Neuroimaging is indicated to rule out alternative diagnoses if the examination is not entirely consistent with a peripheral lesion, if there are prominent risk factors for stroke, if there are neurologic signs or symptoms, or if there is a new headache accompanying the vertigo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/2\">",
"     2",
"    </a>",
"    ]. A younger patient with acute sustained vertigo, with no other neurologic signs or symptoms, and with nystagmus and an examination that is consistent with a peripheral origin (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical manifestations'",
"    </a>",
"    above) does not need imaging if there is improvement within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure of choice is magnetic resonance imaging (MRI) and angiography (MRA). MRI can detect infarction in the posterior fossa on the first day. MRA has a specificity and sensitivity exceeding 95 percent in detecting stenosis or occlusion of the posterior circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) scanning with thin cuts through the cerebellum is an alternative when MRI scanning is not available or in patients with metallic implants. The scan is usually normal in the first hours after an infarct; however, intraparenchymal hemorrhage or significant edema compressing the fourth ventricle will usually be evident immediately. A brain CT scan should therefore be performed if an MRI scan is not immediately available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with vestibular neuritis generally suffer from severe vestibular symptoms for one to two days, followed by a gradual diminution of symptoms and a return of equilibrium. While the acute illness rarely lasts more than several days to a few weeks, residual imbalance and nonspecific dizziness may persist for months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/1\">",
"     1",
"    </a>",
"    ]. Early improvement in symptoms is believed to be largely due to central compensation. Tests of vestibular function, such as caloric testing, show improvement and ultimately recovery as well, but with a significant lag time compared with clinical symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/1\">",
"     1",
"    </a>",
"    ].A positive head thrust sign is of uncertain significance. &nbsp;Two studies have found that abnormal head thrust testing correlates with ongoing symptoms and predicts a more protracted course, especially if it remains positive in follow-up examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], whereas another study found no correlation between abnormal head thrust testing and persistent dizziness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Usually patients suffer from vestibular neuritis only once. In one case series of 103 patients followed for almost 10 years, just two patients had a recurrence, both in the contralateral ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/19\">",
"     19",
"    </a>",
"    ]. However, in one series, 15 percent later developed benign paroxysmal positional vertigo (BPPV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/20\">",
"     20",
"    </a>",
"    ]. Panic disorder has been found to develop in 10 percent of patients with vestibular neuritis over two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential treatments for vestibular neuritis include acute disease-specific treatment with corticosteroids and antiviral agents, symptomatic treatments, and vestibular rehabilitation. There are few formal studies of these therapies in patients with vestibular neuritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute disease-specific treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with corticosteroids during the acute period of vertigo has been shown to improve the recovery of peripheral vestibular function in patients with acute labyrinthitis. A controlled trial randomly assigned 141 patients with vestibular neuritis to one of four treatment groups:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , methylprednisolone plus valacyclovir, or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/22\">",
"     22",
"    </a>",
"    ]. The main outcome measure of vestibular function was the extent of unilateral caloric paresis; this was determined by measuring the mean peak slow-phase nystagmus velocity after caloric irrigation. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (22-day tapering dose schedule) significantly improved vestibular function at 12-month follow-up compared with placebo.",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      1000 mg three times daily for seven days did not improve outcome.",
"     </li>",
"     <li>",
"      Treatment with the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      was no more effective than methylprednisolone alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although outcome as measured by caloric response was improved in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    treatment groups, the study did not assess outcome by the duration and severity of symptoms such as imbalance and chronic spatial disorientation. Therefore, it is not clear that corticosteroid treatment provides long-term symptomatic relief, and further controlled trials are needed to address this issue.",
"   </p>",
"   <p>",
"    Another smaller, randomized, controlled study of 30 patients with vestibular neuritis found somewhat different results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days then a 15 day taper) was associated with improved outcomes on some measures at three and six months, but all objective and subjective outcomes were similar at 12 months. This suggests that corticosteroid therapy may hasten recovery, but does not change the long term prognosis.",
"   </p>",
"   <p>",
"    A meta-analysis examined the efficacy of corticosteroids in four randomized controlled studies (149 patients), including the two previously discussed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/24\">",
"     24",
"    </a>",
"    ]. There was an overall significant effect of corticosteroid therapy on complete caloric recovery at one month but not at 12 months. They found that the small sample size and methodological issues with the included studies precluded firm conclusions regarding the benefit of corticosteroids, particularly on long-term outcomes.",
"   </p>",
"   <p>",
"    Despite these somewhat conflicting results and remaining questions, it seems reasonable to treat presumed viral acute labyrinthitis with corticosteroid therapy. We typically prescribe a 10-day course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ; 60 mg daily on days one through five, 40 mg on day six, 30 mg on day seven, 20 mg on day eight, 10 mg on day nine, and 5 mg on day 10.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic treatments to reduce vertigo, nausea, and vomiting are often employed in the first few days of vestibular neuritis. These include antiemetics, antihistamines, anticholinergics, and benzodiazepines (",
"    <a class=\"graphic graphic_table graphicRef68052 \" href=\"mobipreview.htm?25/16/25868\">",
"     table 3",
"    </a>",
"    ). A nonoral route is generally preferred. Lower doses should be attempted, with upward titration as needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of vertigo\", section on 'Symptomatic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little evidence supporting the use of one agent over another. In general, we prefer using antihistamines and anticholinergics over the benzodiazepines, because they are somewhat less sedating. One trial compared intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    (50 mg) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (2 mg) in 74 patients with acute peripheral vestibulopathy. After two hours, patients treated with dimenhydrinate had better ability to ambulate and were more likely to feel ready to go home compared with patients treated with lorazepam (86 versus 69 percent), who also felt drowsier after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/25\">",
"     25",
"    </a>",
"    ]. Another study compared intramuscular dimenhydrinate (50 mg) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    (2.5 mg) in 40 patients with acute peripheral vertigo and found similar efficacy of the two agents; after 30 minutes, approximately 40 percent of patients felt sufficiently improved to go home without further treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While they provide necessary symptomatic relief in the first 24 to 48 hours, these medications are believed to be somewhat contraindicated after that time. By suppressing vestibular activity, they are believed to impair the central compensation response and delay long-term recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vestibular rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular exercises are believed to be helpful in hastening recovery and improving disability in patients with permanent vestibular injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vertigo\", section on 'Vestibular rehabilitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies of vestibular rehabilitation have not been specific to etiology. However, one study randomly assigned 39 patients with vestibular neuritis to physical therapy versus standard care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/27\">",
"     27",
"    </a>",
"    ]. Evaluation at 30 days revealed that balance function was substantially improved in treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35062/abstract/27\">",
"     27",
"    </a>",
"    ]. Other measures of central compensation appeared similar between the groups.",
"   </p>",
"   <p>",
"    Vestibular rehabilitation is most likely to be efficacious when the patient is referred for a vestibular physical therapy evaluation and completes an individually-designed program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=see_link\">",
"       \"Patient information: Vertigo (a type of dizziness) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=see_link\">",
"       \"Patient information: Dizziness and vertigo (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vestibular neuritis is believed to be an acute viral or postviral inflammatory disorder of the vestibular portion of the eighth cranial nerve. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vestibular neuritis presents with acute onset of vertigo with nausea, vomiting, and gait impairment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of vestibular neuritis overlap with acute vascular events in the cerebellum or brainstem. Clinical features may aid in the distinction of these entities (",
"      <a class=\"graphic graphic_table graphicRef81596 \" href=\"mobipreview.htm?9/14/9453\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no confirmatory test for vestibular neuritis. However, an urgent neuroimaging study (magnetic resonance imaging) is required for patients with acute sustained vertigo whose examination is not entirely consistent with vestibular neuritis, or in patients who are older (&gt;60 years), or have headache, any focal neurologic signs, or vascular risk factors. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with clinical features entirely consistent with vestibular neuritis and no contraindications to steroids, we suggest using a corticosteroid taper (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). While short-term recovery seems to be improved with this therapy, an effect on long-term outcomes is more uncertain. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using vestibular suppressants and antiemetics to limit symptoms in the first 24 to 48 hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest stopping acute symptomatic treatments within 48 hours if the patient's symptoms allow (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some data suggest that these medications interfere with central compensation and long-term recovery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptomatic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest early institution of a vestibular rehabilitation program after acute symptoms subside, as this may hasten long-term recovery, particularly of balance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=see_link\">",
"       \"Treatment of vertigo\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/1\">",
"      Baloh RW. Clinical practice. Vestibular neuritis. N Engl J Med 2003; 348:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/2\">",
"      Hotson JR, Baloh RW. Acute vestibular syndrome. N Engl J Med 1998; 339:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/3\">",
"      DIX MR, HALLPIKE CS. The pathology symptomatology and diagnosis of certain common disorders of the vestibular system. Proc R Soc Med 1952; 45:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/4\">",
"      Silvoniemi P. Vestibular neuronitis. An otoneurological evaluation. Acta Otolaryngol Suppl 1988; 453:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/5\">",
"      Mandal&agrave; M, Nuti D, Broman AT, Zee DS. Effectiveness of careful bedside examination in assessment, diagnosis, and prognosis of vestibular neuritis. Arch Otolaryngol Head Neck Surg 2008; 134:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/6\">",
"      Newman-Toker DE, Kattah JC, Alvernia JE, Wang DZ. Normal head impulse test differentiates acute cerebellar strokes from vestibular neuritis. Neurology 2008; 70:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/7\">",
"      Kattah JC, Talkad AV, Wang DZ, et al. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke 2009; 40:3504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/8\">",
"      Lee CC, Su YC, Ho HC, et al. Risk of stroke in patients hospitalized for isolated vertigo: a four-year follow-up study. Stroke 2011; 42:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/9\">",
"      Lee H, Sohn SI, Cho YW, et al. Cerebellar infarction presenting isolated vertigo: frequency and vascular topographical patterns. Neurology 2006; 67:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/10\">",
"      Norrving B, Magnusson M, Holt&aring;s S. Isolated acute vertigo in the elderly; vestibular or vascular disease? Acta Neurol Scand 1995; 91:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/11\">",
"      Kerber KA, Brown DL, Lisabeth LD, et al. Stroke among patients with dizziness, vertigo, and imbalance in the emergency department: a population-based study. Stroke 2006; 37:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/12\">",
"      Furman JM, Cass SP. Benign paroxysmal positional vertigo. N Engl J Med 1999; 341:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/13\">",
"      Schwartz NE, Venkat C, Albers GW. Transient isolated vertigo secondary to an acute stroke of the cerebellar nodulus. Arch Neurol 2007; 64:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/14\">",
"      Kim JS. Vertigo and gait ataxia without usual signs of lateral medullary infarction: a clinical variant related to rostral-dorsolateral lesions. Cerebrovasc Dis 2000; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/15\">",
"      Becker KJ, Purcell LL, Hacke W, Hanley DF. Vertebrobasilar thrombosis: diagnosis, management, and the use of intra-arterial thrombolytics. Crit Care Med 1996; 24:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/16\">",
"      Kim HA, Hong JH, Lee H, et al. Otolith dysfunction in vestibular neuritis: recovery pattern and a predictor of symptom recovery. Neurology 2008; 70:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/17\">",
"      Nuti D, Mandal&agrave; M, Broman AT, Zee DS. Acute vestibular neuritis: prognosis based upon bedside clinical tests (thrusts and heaves). Ann N Y Acad Sci 2005; 1039:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/18\">",
"      Palla A, Straumann D, Bronstein AM. Vestibular neuritis: vertigo and the high-acceleration vestibulo-ocular reflex. J Neurol 2008; 255:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/19\">",
"      Huppert D, Strupp M, Theil D, et al. Low recurrence rate of vestibular neuritis: a long-term follow-up. Neurology 2006; 67:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/20\">",
"      Baloh RW, Honrubia V, Jacobson K. Benign positional vertigo: clinical and oculographic features in 240 cases. Neurology 1987; 37:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/21\">",
"      Godemann F, Schuller J, Uhlemann H, et al. Psychodynamic vulnerability factors in the development of panic disorders--a prospective trial in patients after vestibular neuritis. Psychopathology 2009; 42:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/22\">",
"      Strupp M, Zingler VC, Arbusow V, et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004; 351:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/23\">",
"      Shupak A, Issa A, Golz A, et al. Prednisone treatment for vestibular neuritis. Otol Neurotol 2008; 29:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/24\">",
"      Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 2011; :CD008607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/25\">",
"      Marill KA, Walsh MJ, Nelson BK. Intravenous Lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. Ann Emerg Med 2000; 36:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/26\">",
"      Irving C, Richman P, Kaiafas C, et al. Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial. Acad Emerg Med 2002; 9:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35062/abstract/27\">",
"      Strupp M, Arbusow V, Maag KP, et al. Vestibular exercises improve central vestibulospinal compensation after vestibular neuritis. Neurology 1998; 51:838.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5102 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35062=[""].join("\n");
var outline_f34_15_35062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cerebellar hemorrhage or infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Brainstem infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute disease-specific treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vestibular rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/29/25051\" title=\"table 1\">",
"      Causes of vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/14/9453\" title=\"table 2\">",
"      Causes vertigo Clin Features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/16/25868\" title=\"table 3\">",
"      Drugs for acute vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=related_link\">",
"      Treatment of vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_15_35063="Nadolol: Drug information";
var content_f34_15_35063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nadolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/37/31317?source=see_link\">",
"    see \"Nadolol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/33/28182?source=see_link\">",
"    see \"Nadolol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corgard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Nadolol;",
"     </li>",
"     <li>",
"      Apo-Nadol&reg;;",
"     </li>",
"     <li>",
"      Corgard&reg;;",
"     </li>",
"     <li>",
"      Novo-Nadolol;",
"     </li>",
"     <li>",
"      Teva-Nadolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Beta-Blocker, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Oral: Initial: 40 mg once daily, increase dosage gradually by 40-80 mg increments at 3- to 7-day intervals until optimum clinical response is obtained; usual dose: 40-80 mg daily; maximum dose: 240 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 40 mg/day, increase dosage gradually by 40-80 mg increments until optimum blood pressure reduction achieved. Usual dosage range (JNC 7): 40-120 mg once daily; doses up to 240-320 mg/day in hypertension may be necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Variceal hemorrhage prophylaxis (unlabeled use)",
"     </b>",
"     (Garcia-Tsao, 2007): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary prophylaxis:",
"     </i>",
"     Initial: 40 mg once daily; adjust to maximal tolerated dose.",
"     <b>",
"      Note:",
"     </b>",
"     Risk factors for hemorrhage include Child-Pugh class B/C or variceal red wale markings on endoscopy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Secondary prophylaxis:",
"     </i>",
"     Initial: 40 mg once daily; adjust to maximal tolerated dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyrotoxicosis (unlabeled use):",
"     </b>",
"     Oral: 40-160 mg once daily (Bahn, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F198899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, 20 mg/day) and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F198900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 40-60 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dosage adjustments for dialysis are not provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD requiring hemodialysis: Administer dose postdialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis: Administer every 40-60 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F198901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corgard&reg;: 20 mg, 40 mg, 80 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9537073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension and angina pectoris; prophylaxis of migraine headaches",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6143083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primary and secondary prophylaxis of variceal hemorrhage; management of thyrotoxicosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F198936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Corgard&reg; may be confused with Cognex&reg;, Coreg&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nadolol may be confused with Mandol brand name for cefamandole [Belgium, Netherlands, New Zealand, Russia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased sexual ability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, palpitation, edema, CHF, reduced peripheral circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Mental depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea or constipation, nausea, vomiting, stomach discomfort",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arrhythmias, chest pain, confusion (especially in the elderly), depression, dyspnea, hallucinations, leukopenia, orthostatic hypotension, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nadolol or any component of the formulation; bronchial asthma; sinus bradycardia; sinus node dysfunction; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition (efficacy of nadolol in HF has not been demonstrated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustments are required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal:",
"     <b>",
"      [U.S. Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia.",
"     </b>",
"     Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F198890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, garlic, yohimbe, ginseng (may worsen hypertension). Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies; therefore, the manufacturer classifies nadolol as pregnancy category C. Nadolol crosses the placenta and is measurable in infant serum after birth. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. Nadolol is indicated for the treatment of hypertension, but due to its long half-life and potential effects to the fetus, other agents may be more appropriate for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution consider risk:benefit (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F198881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nadolol is excreted into breast milk in concentrations higher than the maternal serum. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. The time to peak milk concentration is 6 hours after the oral dose, the half-life of nadolol in breast milk is similar to that in the maternal serum, and nadolol can still be detected in breast milk for several days after the last maternal dose.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F198882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F198879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Corgard Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $384.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $449.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $617.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nadolol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $92.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $108.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $398.44",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F198883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anabet (PT);",
"     </li>",
"     <li>",
"      Apo-Nadolol (NZ);",
"     </li>",
"     <li>",
"      Corgard (AR, BB, BE, BM, BR, BS, BZ, CH, CL, CN, CO, CZ, ES, FR, GB, GY, IE, IT, JM, KE, LU, MX, MY, NG, NL, PE, PH, PK, PL, RU, SR, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM);",
"     </li>",
"     <li>",
"      Farmagard (ID);",
"     </li>",
"     <li>",
"      Solgol (AT, DE, ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks response to beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic stimulation; does not exhibit any membrane stabilizing or intrinsic sympathomimetic activity. Nonselective beta-adrenergic blockers (propranolol, nadolol) reduce portal pressure by producing splanchnic vasoconstriction (beta",
"     <sub>",
"      2",
"     </sub>",
"     effect) thereby reducing portal blood flow.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 17-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 30% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 10-24 hours; prolonged with renal impairment; End-stage renal disease: 45 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, \"ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/ 21510801/pubmed\" id=\" 21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia-Tsao G, Sanyal AJ, Grace ND, et al, &ldquo;Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2007, 46(3):922-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/17879356/pubmed\" id=\"17879356\" target=\"_blank\">",
"        17879356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, \"Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villaneuva C, Minana J, Ortiz J, et al, &ldquo;Endoscopic Ligation Compared With Combined Treatment With Nadolol and Isosorbide Mononitrate to Prevent Recurrent Variceal Bleeding,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(9):647-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/11547718/pubmed\" id=\"11547718\" target=\"_blank\">",
"        11547718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinetics",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Hear J",
"      </i>",
"      , 2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/15/35063/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9672 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35063=[""].join("\n");
var outline_f34_15_35063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709161\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198895\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198928\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198898\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198899\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198900\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198901\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198871\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198858\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9537073\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198874\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6143083\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198936\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198926\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198877\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198862\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838219\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198867\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198890\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198868\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198880\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198903\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198881\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198882\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198879\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198883\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198861\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198876\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/37/31317?source=related_link\">",
"      Nadolol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/33/28182?source=related_link\">",
"      Nadolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_15_35064="Portopulmonary hypertension";
var content_f34_15_35064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Portopulmonary hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35064/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35064/contributors\">",
"     Lewis J Rubin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35064/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35064/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/15/35064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portopulmonary hypertension (PPHTN) refers to pulmonary arterial hypertension that is associated with portal hypertension; it is a well recognized complication of chronic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In this topic review, the definition, classification, epidemiology, and pathogenesis of PPHTN are discussed. In addition, its clinical presentation, diagnosis, treatment, and prognosis are reviewed. Hepatopulmonary syndrome, a separate but related condition characterized by hypoxemic respiratory insufficiency due to increased intrapulmonary shunting, is discussed separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3640?source=see_link\">",
"     \"Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPHTN is considered present when pulmonary arterial hypertension (PAH) exists in a patient who has coexisting portal hypertension, and no alternative cause of the PAH exists (eg, collagen vascular disease, congenital heart disease, or certain drugs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAH is defined according to right heart catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean pulmonary artery pressure (mPAP) &gt;25 mmHg at rest",
"     </li>",
"     <li>",
"      Pulmonary capillary wedge pressure (PCWP) &lt;15 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional supportive data include an increased pulmonary vascular resistance and transpulmonary gradient. The transpulmonary gradient is defined as the difference between the pulmonary arterial diastolic blood pressure and the pulmonary capillary wedge pressure.",
"   </p>",
"   <p>",
"    Portal hypertension is inferred from history, physical examination, imaging, or pathology that suggests chronic liver disease or portal hypertension. It can be confirmed by hepatic venous catheterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension was traditionally classified as either idiopathic pulmonary arterial hypertension (IPAH, formerly known as primary pulmonary hypertension) or secondary pulmonary hypertension. In an effort to organize on a mechanistic basis, pulmonary hypertension was reclassified by the World Health Organization (WHO) into five groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have pulmonary hypertension (PH) (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    PPHTN is a type of group 1 PAH. This group also includes IPAH (sporadic and hereditary) and PAH due to drugs and toxins, connective tissue diseases, HIV infection, congenital heart disease, schistosomiasis, chronic hemolytic anemia, persistent pulmonary hypertension of the newborn, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO classification system is shown in the table and discussed in greater detail elsewhere (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of PPHTN depends upon the patient population studied, with increasing frequency among patients with more severe liver disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 17,901 autopsied patients, pathologic changes consistent with pulmonary arterial hypertension were found in 0.7 percent of patients with cirrhosis. Although infrequent, it was more than five times the expected frequency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of 507 patients with portal hypertension detected PAH in 2 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several studies indicate that the prevalence of PPHTN is highest in patients with end-stage liver disease undergoing evaluation for liver transplantation, with rates ranging from 3.5 to 16.1 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/8-13\">",
"       8-13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portal hypertension must exist for PPHTN to develop. Chronic liver disease without portal hypertension does not cause PPHTN. Causes of portal hypertension that have been described in patients with PPHTN include cirrhosis, portal vein thrombosis, hepatic vein sclerosis, congenital portal circulation abnormalities, and periportal fibrosis without cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of PPHTN is unknown, although numerous theories have been proposed. The most widely accepted hypothesis is that a humoral substance (which would normally be metabolized by the liver) is able to reach the pulmonary circulation through portosystemic collaterals, resulting in PPHTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/16\">",
"     16",
"    </a>",
"    ]. Candidates for this humoral substance include serotonin, interleukin-1, endothelin-1, glucagon,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    , thromboxane B2, and vasoactive intestinal peptide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/14,17-19\">",
"     14,17-19",
"    </a>",
"    ]. Increased plasma concentrations of these mediators have been detected in patients with portal hypertension.",
"   </p>",
"   <p>",
"    Alternatively, a genetic predisposition may exist. The observation that PPHTN is infrequent and sporadic among patients with portal hypertension is consistent with this proposal. A gene responsible for some cases of familial PAH has been localized to chromosome 2 (locus 2q33) and defective function of the bone morphogenetic protein receptor type II (BMPR2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. This or similar defects may contribute to PPHTN.",
"   </p>",
"   <p>",
"    Thromboembolism from the portal venous system also has been proposed as a cause of PPHTN. In this theory, thrombi from the portal circulation pass through portosystemic shunts and reach the pulmonary circulation, thus producing PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Arguing against this proposal, a large autopsy study failed to show a significant number of thrombi simultaneously in the portal and pulmonary vascular beds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/26\">",
"     26",
"    </a>",
"    ], and some histopathologic features suggest that the pulmonary arterial thrombi sometimes observed in PPHTN usually arise in situ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperdynamic circulation seen in patients with liver disease may also contribute to the development of PPHTN, with increased blood flow through the pulmonary vascular bed and increased sheer stress on the vascular wall, possibly resulting in PAH. However, this hypothesis is not supported by data suggesting that increased blood flow is readily accommodated by the pulmonary vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary histopathologic findings in PPHTN and IPAH are indistinguishable (",
"    <a class=\"graphic graphic_picture graphicRef66276 \" href=\"mobipreview.htm?40/33/41490\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. These findings include vasoconstriction, remodeling of the muscular pulmonary artery walls, and in situ thrombosis.",
"   </p>",
"   <p>",
"    Medial hypertrophy is an early and potentially reversible form of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/27\">",
"     27",
"    </a>",
"    ]. As the diseases advances, medial hypertrophy becomes a component of pulmonary arteriopathy. Two subtypes of pulmonary arteriopathy have been described in patients with PPHTN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plexogenic pulmonary arteriopathy is characterized by medial hypertrophy, intimal fibrosis, and lesions involving the entire vessel wall.",
"     </li>",
"     <li>",
"      Thrombotic pulmonary arteriopathy is characterized by medial hypertrophy, thrombosis, and eccentric, nonlaminar intimal fibrosis. It may arise from in situ thrombosis, rather than emboli.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is uncertain whether each subtype is a different stage of the same disease or a different response to injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PPHTN have clinical evidence of both portal hypertension and PAH. Fewer patients present with complaints related to portal hypertension only, without pulmonary symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/3\">",
"     3",
"    </a>",
"    ]. Rarely, a patient may present with pulmonary symptoms related to the PAH, without evidence of portal hypertension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Portal hypertension &ndash; Manifestations of portal hypertension typically precede those of PAH, with the interval between the first manifestation of portal hypertension and the documentation of PAH ranging from 2 to 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/16,29\">",
"       16,29",
"      </a>",
"      ]. Clinical manifestations of portal hypertension are discussed in detail elsewhere.",
"     </li>",
"     <li>",
"      Pulmonary arterial hypertension &ndash; The pulmonary symptoms associated with PPHTN are similar to those associated with other types of PAH. In a series of 78 patients with PPHTN, the most common presenting pulmonary symptoms were dyspnea on exertion, syncope, chest pain, fatigue, hemoptysis, and orthopnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/29\">",
"       29",
"      </a>",
"      ]. The most common physical findings were an accentuated pulmonic component of the second heart sound, a systolic murmur, and edema. A retrospective study compared the characteristics of 30 patients with PPHTN, 30 patients with IPAH, and 30 patients with chronic liver disease alone, who were awaiting transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/30\">",
"       30",
"      </a>",
"      ]. The patients with PPHTN had elevated mPAP similar to those with IPAH; however, they had reduced systemic vascular resistance and elevated cardiac index similar to those with chronic liver disease alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tricuspid regurgitation is common in patients with PAH and is audible as a systolic murmur located along the lower left sternal border that is accentuated with inspiration. Dependent pitting edema is a sign of right ventricular dysfunction. Chest radiographs demonstrate prominent pulmonary arteries and cardiomegaly in most patients. The electrocardiogram (ECG) often demonstrates right ventricular hypertrophy, right axis deviation, and a right bundle branch block. In one study, only 4 percent of patients had a normal ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having PAH undergo extensive diagnostic testing, which is aimed at identifying the cause of PAH and confirming the presence of PAH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common diagnostic tests include echocardiography, ECG, chest radiography or computed tomography, pulmonary function testing, polysomnography, ventilation-perfusion scanning or pulmonary angiography, autoantibody testing, HIV testing, and liver function testing (",
"    <a class=\"graphic graphic_algorithm graphicRef72553 \" href=\"mobipreview.htm?4/20/4416\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/31\">",
"     31",
"    </a>",
"    ]. Testing should be prioritized according to the patient's history and physical examination. IPAH is the diagnosis of exclusion, if an alternative cause cannot be identified.",
"   </p>",
"   <p>",
"    Right heart catheterization is necessary to confirm the diagnosis of PAH and estimate its severity. Hepatic venous wedge pressure should also be measured during catheterization to determine the severity of portal hypertension if PPHTN is suspected.",
"   </p>",
"   <p>",
"    Diagnosis of PPHTN is confirmed when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PAH exists, as indicated by an elevated mPAP, PVR, and transpulmonary gradient during right heart catheterization",
"     </li>",
"     <li>",
"      Portal hypertension exists, as indicated by an elevated hepatic venous pressure during hepatic vein catheterization",
"     </li>",
"     <li>",
"      An alternative cause of the PAH cannot be identified",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the treatment options for PPHTN have been extrapolated from studies performed in patients with IPAH. The impact of these treatment options on patients with PPHTN is still under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Baseline assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline assessment of the severity of the PPHTN is essential because response to therapy will be measured as the change from baseline. In addition to the patient's baseline hemodynamics determined by right heart catheterization during the diagnostic evaluation, the patient's exercise capacity should be tested and the New York Heart Association (NYHA) or World Health Organization (WHO) functional class determined (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30616613\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PPHTN are at risk for in situ pulmonary vascular thrombosis and thromboembolic disease due to venous stasis, slowed pulmonary blood flow, and right heart enlargement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients with PPHTN also tend to have problems related to volume overload with ascites and anasarca. As a result, anticoagulant and diuretic therapy are often used in patients with PPHTN:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticoagulation &ndash; Several studies involving patients with IPAH have suggested that anticoagulation might improve survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. Although patients with PPHTN have not been studied, it may be reasonable to treat such patients with oral anticoagulants if no contraindications exist, particularly when cardiac output is reduced due to right heart failure. When anticoagulant therapy is administered, we advocate a goal INR of 1.5 due to the increased risk of hemorrhage in patients with chronic liver disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21446?source=see_link\">",
"       \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diuretics &ndash; The use of diuretics in patients with cirrhosis, including the diuretic regimen and concerns related to fluid removal and hypokalemia, are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H8#H8\">",
"       \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of beta-blockers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transjugular intrahepatic portosystemic shunts (TIPS) may be harmful to patients with PPHTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/1,36\">",
"     1,36",
"    </a>",
"    ]. Therefore, beta-blockers and TIPS are not routine therapies for PPHTN. In patients with PPHTN for whom beta-blockers or TIPS is indicated for portal hypertension, the decision to initiate these therapies should be made on a case by case basis after carefully weighing the risks versus the potential benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Advanced therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced therapy refers to the administration of agents with complex mechanisms of action including vasodilation, vascular growth, and remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/32,37,38\">",
"     32,37,38",
"    </a>",
"    ]. Agents that have been used to treat PPHTN include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    . Most reports are from case series and small observational studies; thus, there are insufficient data to recommend a specific treatment.",
"   </p>",
"   <p>",
"    In general, patients are candidates for advanced therapy if they remain NYHA or WHO functional class II, III, or IV despite optimization of the underlying cause of their portal hypertension (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"     table 3",
"    </a>",
"    ). Selection of patients for advanced therapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with PPHTN do not need to undergo vasoreactivity testing because pure vasodilator therapy (eg, calcium channel blockers) should not be administered regardless of the outcome. Pure vasodilators do not benefit patients with PPHTN and can cause significant hypotension due to systemic vasodilation and decreased right ventricular filling. Patients with PPHTN are particularly susceptible to this side effect because low systemic vascular resistance usually exists in chronic liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Epoprostenol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     Epoprostenol",
"    </a>",
"    (prostacyclin, Flolan) is a potent vasodilator with anti-platelet aggregating and antiproliferative properties that improves exercise tolerance and prolongs survival in patients with IPAH, regardless of whether vasoreactivity exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. In patients with PPHTN, continuous intravenous epoprostenol improves hemodynamics and exercise performance; as a result, it is often considered as a bridge to liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series of seven patients with PPHTN who were treated with continuous intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      demonstrated that the NYHA functional class improved in all patients one year after the initiation of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/44\">",
"       44",
"      </a>",
"      ]. There were also significant improvements in exercise duration, mean pulmonary artery pressure, and pulmonary vascular resistance, compared to baseline.",
"     </li>",
"     <li>",
"      In an observational study, 14 patients with advanced liver disease and moderate to severe pulmonary hypertension (defined as a mPAP &gt;35 mmHg) received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/45\">",
"       45",
"      </a>",
"      ]. Epoprostenol was associated with a reduction of mPAP, a reduction of PVR, and an increase in cardiac output (CO). Ten patients were maintained on a continuous intravenous infusion and six of them underwent repeat right heart catheterization that confirmed long-term reduction of PVR. Six of the ten patients who received continuous epoprostenol died during the study, raising the possibility that the therapy could have adverse effects on hepatic function, portal hypertension, or other aspects of chronic liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    therapy include jaw pain, diarrhea, erythema, arthralgias, and a high cardiac output state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/32,49\">",
"     32,49",
"    </a>",
"    ]. More severe adverse effects are usually attributable to the complex delivery system including infection, thrombosis, pump malfunction, and interruption of the infusion, which can be complicated by rebound pulmonary hypertension. Hypersplenism has been reported in patients with PPHTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/50\">",
"     50",
"    </a>",
"    ]. It is unclear whether the risk of adverse outcomes during epoprostenol therapy is greater in patients with PPHTN than IPAH.",
"   </p>",
"   <p>",
"    The decision to initiate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    therapy must consider many factors, including potential long-term benefit, risk of complications, and the patient's ability to manage the delivery system. The administration of epoprostenol is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bosentan and ambrisentan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    is a dual endothelin-A and endothelin-B receptor antagonist, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"     ambrisentan",
"    </a>",
"    is a more selective endothelin-A receptor antagonist. Both are administered orally and are beneficial for patients with IPAH. They may also be beneficial for patients with PPHTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/51-60\">",
"     51-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty-four consecutive patients with PPHTN were treated with first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      for a mean of 43 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/60\">",
"       60",
"      </a>",
"      ]. Significant improvements were noted in NYHA functional class, six-minute walk distance, and hemodynamics. Plasma concentrations of bosentan were higher in these patients than in a cohort with idiopathic pulmonary artery hypertension. Four patients died during follow-up and seven had significant elevation in liver enzymes.",
"     </li>",
"     <li>",
"      A retrospective cohort study of 18 patients who had severe PPHTN treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      for up to three years found 1-, 2-, and 3-year survival rates of 94, 89, and 89 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/58\">",
"       58",
"      </a>",
"      ]. The survival rates were better than those observed in patients treated with inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      . In addition, an observational study of 11 patients with severe PPHTN who were treated with bosentan for one year found that the six-minute walking distance increased and the PVR decreased, compared to baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study followed 13 patients with PPHTN who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"       ambrisentan",
"      </a>",
"      for a median of 613 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/59\">",
"       59",
"      </a>",
"      ]. The mean pulmonary artery pressure decreased from a median of 58 mmHg to 41 mmHg, while the vascular resistance decreased from a median of 445",
"      <span class=\"nowrap\">",
"       dynes/s/cm",
"       <sup>",
"        5",
"       </sup>",
"      </span>",
"      to 174",
"      <span class=\"nowrap\">",
"       dynes/s/cm",
"       <sup>",
"        5",
"       </sup>",
"       .",
"      </span>",
"      Liver function testing was unchanged after 12 months of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with PPHTN should have liver function monitored closely during endothelin receptor antagonist therapy, since the agents have been associated with hepatotoxicity in unselected patients with IPAH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    is an oral phosphodiesterase inhibitor that has proven to benefit patients with IPAH. Case reports describe the successful use of sildenafil to treat PPHTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In addition, an observational study followed 14 patients with moderate to severe PPHTN who were administered sildenafil (50 mg, three times per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/63\">",
"     63",
"    </a>",
"    ]. In eight patients, sildenafil was the first therapy, while sildenafil was added to preexisting inhaled prostanoid therapy in the remaining six patients. Among the 12 patients who completed the study, there was a reduction of mPAP and PVR at three months, but not at one year, compared to baseline. Six-minute walking distance was improved at both three months and one year. There was no difference whether sildenafil was used as monotherapy or in combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Iloprost",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     Iloprost",
"    </a>",
"    is a prostacyclin analogue that is beneficial to patients with IPAH when administered by inhalation. Case reports describe successful use of inhaled or intravenous iloprost in patients with PPHTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In addition, a retrospective cohort study of 13 patients who had severe PPHTN treated with inhaled iloprost for up to three years found one-, two-, and three-year survival rates of 77, 62, and 46 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/58\">",
"     58",
"    </a>",
"    ]. These survival rates are better than historical controls, but poorer than those seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/29,58\">",
"     29,58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Bosentan and ambrisentan'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation is a possible treatment for PPHTN, although there are no hemodynamic criteria to determine candidacy for liver transplantation have not been established. Patients with PPHTN who have successfully undergone liver transplantation have demonstrated improvement or complete normalization of their PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/47,48,66-69\">",
"     47,48,66-69",
"    </a>",
"    ]. Outcomes due to liver transplantation and advanced therapy have never been compared.",
"   </p>",
"   <p>",
"    It is uncertain whether the severity of the PAH affects outcomes following liver transplantation. Limited data suggest that severe PAH (systolic PAP &gt;60 mmHg) is associated with high perioperative risk and poor clinical outcome, while mild to moderate PAH does not influence mortality after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/1,8-11,69\">",
"     1,8-11,69",
"    </a>",
"    ]. As an example, a retrospective study of 1205 patients who underwent liver transplantation compared those with PAH to those without PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/8\">",
"     8",
"    </a>",
"    ]. The three year mortality rate for patients without PAH, with mild PAH (systolic PAP 30 to 44 mmHg), with moderate PAH (systolic PAP 45 to 59 mmHg), and with severe PAH (systolic PAP &gt;60 mmHg) was 28, 33, 35, and 71 percent, respectively.",
"   </p>",
"   <p>",
"    The model for End-stage Liver Disease (MELD) scoring system is used to predict survival among patients with chronic liver disease, with higher scores correlating with lower survival. Patients with PPHTN should have their MELD score upgraded ten percent every three months while they are on the liver transplantation waiting list; otherwise, the MELD score will underestimate their mortality risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link&amp;anchor=H14#H14\">",
"     \"Model for End-stage Liver Disease (MELD)\", section on 'Other MELD exceptions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PPHTN may have worse outcomes than patients with other types of group 1 PAH. This was suggested by a retrospective cohort study of 174 patients that was performed using data from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (ie, the REVEAL Registry) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/70\">",
"     70",
"    </a>",
"    ]. Compared with idiopathic and familial pulmonary arterial hypertension, patients with PPHTN had worse two-year survival (67 versus 85 percent) and five-year survival (40 versus 64 percent), despite having better hemodynamic measurements and functional class assignments at the time of diagnosis.",
"   </p>",
"   <p>",
"    It is possible that the poorer outcomes reflect the observation that, prior to the REVEAL Registry, treatment of PPHTN with advanced therapy was frequently delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/70\">",
"     70",
"    </a>",
"    ]. This is supported by evidence that indicates that advanced therapy improves outcome. In a series of 154 patients with PPHTN, survival rates at one-, three-, and five-years were 88, 75, and 68 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/71\">",
"     71",
"    </a>",
"    ]. Approximately one-third of patients had received advanced therapy during the study. These survival rates are more encouraging than the six-month survival rate of 50 percent that was reported by a study of patients who did not receive advanced therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35064/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with portopulmonary hypertension (PPHTN) present with clinical evidence of portal hypertension and pulmonary symptoms due to pulmonary arterial hypertension (PAH). Fewer patients have evidence of portal hypertension without pulmonary symptoms. Reciprocally, pulmonary symptoms without evidence of portal hypertension are rare. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected of having PAH undergo extensive diagnostic testing, which is aimed at identifying the cause of the PAH and confirming the presence of the PAH (",
"      <a class=\"graphic graphic_algorithm graphicRef72553 \" href=\"mobipreview.htm?4/20/4416\">",
"       algorithm 1",
"      </a>",
"      ). PPHTN is confirmed when PAH exists during right heart catheterization, portal hypertension exists during hepatic vein catheterization, and an alternative cause of the PAH cannot be identified. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with PPHTN and reduced cardiac output due to right heart failure receive anticoagulant therapy if no contraindications exist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Anticoagulant therapy should be considered on a case by case basis for other patients with PPHTN, after carefully weighing the risks versus the benefits. When anticoagulant therapy is administered, we advocate a goal INR of 1.5 due to the increased risk of hemorrhage in patients with chronic liver disease. (See",
"      <a class=\"local\" href=\"#H30616613\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with PPHTN who remain New York Heart Association (NYHA) or World Health Organization (WHO) functional class II, III, or IV despite optimal treatment of the underlying cause of their portal hypertension be treated with advanced therapy that has efficacy in idiopathic pulmonary arterial hypertension (IPAH) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We prefer intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      given more extensive clinical experience and some observational evidence of benefit. Other therapies that can be tried include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"       ambrisentan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      . The NYHA and WHO functional classes are shown in the tables (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Advanced therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver transplantation is a possible treatment for PPHTN. Reports describe patients with PPHTN who have successfully undergone liver transplantation with improvement or complete normalization of their PAH. We suggest that patients with PPHTN be referred for liver transplantation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients who have a good clinical response to advanced therapy, the timing of liver transplantation can be determined by the status of the liver disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PPHTN, beta-blockers and transjugular intrahepatic portosystemic shunts (TIPS) are potentially harmful and, therefore, they are not indicated as treatments for PPHTN. (See",
"      <a class=\"local\" href=\"#H30616613\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/1\">",
"      Rodr&iacute;guez-Roisin R, Krowka MJ, Herv&eacute; P, et al. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/2\">",
"      McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/3\">",
"      Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/4\">",
"      Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/5\">",
"      Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003; 123:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/6\">",
"      Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/7\">",
"      Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/8\">",
"      Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/9\">",
"      Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 71:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/10\">",
"      Taura P, Garcia-Valdecasas JC, Beltran J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996; 83:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/11\">",
"      Plevak D, Krowka M, Rettke S, et al. Successful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc 1993; 25:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/12\">",
"      Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/13\">",
"      Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/14\">",
"      Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/15\">",
"      Cohen MD, Rubin LJ, Taylor WE, Cuthbert JA. Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension. Hepatology 1983; 3:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/16\">",
"      Lebrec D, Capron JP, Dhumeaux D, Benhamou JP. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979; 120:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/17\">",
"      Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 1996; 17:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/18\">",
"      Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999; 54:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/19\">",
"      Maruyama T, Ohsaki K, Shimoda S, et al. Thromboxane-dependent portopulmonary hypertension. Am J Med 2005; 118:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/20\">",
"      Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/21\">",
"      Deng Z, Haghighi F, Helleby L, et al. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med 2000; 161:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/22\">",
"      Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/23\">",
"      Kimura N, Matsuo R, Shibuya H, et al. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 2000; 275:17647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/24\">",
"      NAEYE RL. \"Primary\" pulmonary hypertension with coexisting portal hypertension. A retrospective study of six cases. Circulation 1960; 22:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/25\">",
"      Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/26\">",
"      Matsubara O, Nakamura T, Uehara T, Kasuga T. Histometrical investigation of the pulmonary artery in severe hepatic disease. J Pathol 1984; 143:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/27\">",
"      Pietra GG. Histopathology of primary pulmonary hypertension. Chest 1994; 105:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/28\">",
"      Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 1996; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/29\">",
"      Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/30\">",
"      Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/31\">",
"      Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/32\">",
"      Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/33\">",
"      Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/34\">",
"      Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/35\">",
"      Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/36\">",
"      Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/37\">",
"      Rich S. The medical treatment of primary pulmonary hypertension. Proven and promising strategies. Chest 1994; 105:17S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/38\">",
"      Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/39\">",
"      Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs 1998; 56:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/40\">",
"      Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/41\">",
"      Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/42\">",
"      Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/43\">",
"      Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/44\">",
"      McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/45\">",
"      Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/46\">",
"      Plotkin JS, Kuo PC, Rubin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/47\">",
"      Tan HP, Markowitz JS, Montgomery RA, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001; 7:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/48\">",
"      Kett DH, Acosta RC, Campos MA, et al. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001; 7:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/49\">",
"      Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/50\">",
"      Findlay JY, Plevak DJ, Krowka MJ, et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/51\">",
"      Halank M, Miehlke S, Hoeffken G, et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/52\">",
"      Kuntzen C, G&uuml;lberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/53\">",
"      Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006; 36 Suppl 3:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/54\">",
"      St&auml;hler G, von Hunnius P. Successful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest 2006; 36 Suppl 3:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/55\">",
"      Neuhofer W, G&uuml;lberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006; 36 Suppl 3:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/56\">",
"      Hinterhuber L, Graziadei IW, K&auml;hler CM, et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/57\">",
"      Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/58\">",
"      Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/59\">",
"      Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/60\">",
"      Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2013; 41:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/61\">",
"      Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005; 24:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/62\">",
"      Latiff K, Meanger J, Mills J, Ghildyal R. Sequence and structure relatedness of matrix protein of human respiratory syncytial virus with matrix proteins of other negative-sense RNA viruses. Clin Microbiol Infect 2004; 10:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/63\">",
"      Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/64\">",
"      Halank M, Marx C, Miehlke S, Hoeffken G. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004; 39:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/65\">",
"      Minder S, Fischler M, Muellhaupt B, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/66\">",
"      Koneru B, Ahmed S, Weisse AB, et al. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994; 58:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/67\">",
"      De Wolf AM, Scott VL, Gasior T, Kang Y. Pulmonary hypertension and liver transplantation. Anesthesiology 1993; 78:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/68\">",
"      Schott R, Chaouat A, Launoy A, et al. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/69\">",
"      Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/70\">",
"      Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012; 141:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35064/abstract/71\">",
"      Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8266 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35064=[""].join("\n");
var outline_f34_15_35064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Baseline assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30616613\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Advanced therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Epoprostenol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bosentan and ambrisentan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Iloprost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8266\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8266|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/20/4416\" title=\"algorithm 1\">",
"      Evaluation of suspected PH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8266|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/33/41490\" title=\"picture 1\">",
"      Small pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8266|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/38/43628\" title=\"table 1\">",
"      WHO pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/47/25339\" title=\"table 3\">",
"      Classification PH function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3640?source=related_link\">",
"      Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21446?source=related_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_15_35065="Staging work-up and surveillance after treatment of melanoma";
var content_f34_15_35065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Staging work-up and surveillance after treatment of melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Antonio C Buzaid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Jeffrey E Gershenwald, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Merrick I Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/15/35065/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/15/35065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests and imaging studies are necessary to accurately stage patients with cancer prior to definitive treatment. However, the staging evaluations used for cancer patients both at the time of initial diagnosis and for follow-up after the initial treatment are often excessive. There are few, if any, established guidelines that define the appropriate tests for the initial evaluation and subsequent follow-up in patients with melanoma.",
"   </p>",
"   <p>",
"    Practical stage-specific guidelines for the evaluation and follow-up of patients with melanoma are presented here. The melanoma staging system and a review of imaging studies useful in the evaluation of melanoma are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15450?source=see_link\">",
"     \"Imaging studies in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL STAGE I AND II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma has the potential to metastasize to any organ; common sites of dissemination include the skin, subcutaneous tissues, lymph nodes, liver, bone, lung, brain, and visceral organs.",
"   </p>",
"   <p>",
"    However, there is no role for routine imaging studies in asymptomatic patients with clinical stages I and II disease (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ), as the identification of metastatic disease in this setting is negligible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest x-ray &ndash; The detection rate of occult metastases with chest x-ray is minimal at the time of diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/1-6\">",
"       1-6",
"      </a>",
"      ]. In a series of 876 asymptomatic patients with localized melanoma, only one patient (0.1 percent) had a true-positive chest film demonstrating pulmonary metastases, while false positive tests occurred in approximately 15 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/1\">",
"       1",
"      </a>",
"      ]. Nonetheless, chest X-rays often show nonspecific abnormalities that can serve as a baseline for future examinations.",
"     </li>",
"     <li>",
"      CT studies &ndash; Computerized tomography (CT) has very limited value for detecting unsuspected visceral metastases in asymptomatic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/3,5-7\">",
"       3,5-7",
"      </a>",
"      ]. As an example, 151 patients in one series were staged with CT of the chest and abdomen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with primary tumors of the head or neck also had a CT of the neck, while those with primary tumors below the waist had a pelvic CT. A total of 29 patients (19 percent) had suspicious scans: in 24 of these, the abnormalities were benign processes (false positives); in three (2 percent) second primary tumors were found (non-Hodgkin lymphoma, Hodgkin lymphoma, and renal cell carcinoma). Only two patients (1.3 percent) had melanoma metastases. Routine evaluation with brain CT in many other series has not revealed a single case of metastasis in hundreds of patients studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/3,5-7\">",
"       3,5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PET &ndash; Positron emission tomography (PET) also has not been useful in the staging work-up of patients with stage I and II disease due to its low sensitivity for occult regional lymphatic disease or unsuspected distant metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. In addition, there is a relatively high rate of false positive examinations. In about 1 percent of patients, PET may detect an incidental second primary tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/11\">",
"       11",
"      </a>",
"      ].Similar results have been observed with bone,",
"      <span class=\"nowrap\">",
"       liver/spleen,",
"      </span>",
"      and brain scans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/3-6,12-15\">",
"       3-6,12-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymphatic mapping and sentinel lymph node &ndash; The indications for lymphatic mapping and sentinel lymph node (SLN) biopsy in patients with clinical stage I and II disease are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link\">",
"       \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2817837\">",
"    <span class=\"h1\">",
"     STAGE III DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage III disease include those with clinical stage I or II disease, in whom occult lymph node disease is diagnosed at sentinel lymph node (SLN) biopsy, and those with clinical stage III disease, based upon the presence of clinically palpable nodes (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). Patients with other forms of lymphatic regional metastases (satellite lesions, in transit metastases) are also classified as stage III.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2817844\">",
"    <span class=\"h2\">",
"     Positive sentinel lymph node",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common utilization of SLN biopsy in patients with a clinical stage I or II melanoma identifies a subset of patients with clinically occult, pathologically positive SLNs (stage III) who are at increased risk for the subsequent development of disseminated disease compared to otherwise similar patients whose SLNs are negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with positive SLNs often undergo comprehensive imaging studies either before completion lymphadenectomy or following surgery when they are being considered for adjuvant therapy or participation in adjuvant therapy trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link&amp;anchor=H2#H2\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Prognostic factors affecting staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the frequent use of such studies, routine staging with CT, magnetic resonance imaging (MRI), or PET does not appear to be useful in this setting.",
"   </p>",
"   <p>",
"    The low frequency of detectable metastases found with extensive imaging is illustrated by three large single institution series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series from M. D. Anderson Cancer Center (MDACC), 314 patients with a positive SLN were evaluated, of whom 270 underwent CT of the chest and abdomen and either CT or MRI of the head [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/17\">",
"       17",
"      </a>",
"      ]. Occult metastases were confirmed in five patients (1.9 percent), nearly all of whom had significant tumor burden in the sentinel node and ulcerated primary tumors. Routine screening identified second primary tumors in 10 patients (3.7 percent), and the false positive rate was 12 percent.",
"     </li>",
"     <li>",
"      In a report from the University of California at San Francisco, CT of the chest, abdomen, and pelvis detected metastases in one of 185 patients (0.5 percent) with a positive SLN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/18\">",
"       18",
"      </a>",
"      ]. This patient had an ulcerated primary lesion that was &gt;4 mm thick as well as extensive involvement in the sentinel lymph node. No brain metastases were identified in 112 patients studied with either MRI or CT.",
"     </li>",
"     <li>",
"      In a series from Memorial Sloan Kettering Cancer Center (MSKCC), 4 of 107 (3.7 percent) patients with positive SLNS had distant metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/19\">",
"       19",
"      </a>",
"      ]. All four had thick primary tumors and a significant tumor burden within the SLN. The role of PET was evaluated in this series, with results similar to CT alone. If body CT scans and PET had been restricted to patients with thick primaries, the true positive rate would have been 13 percent; if CT and PET were restricted to patients with both thick primaries and macrometastases in the sentinel node, the true positive rate would have been 16 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, most of the occult distant metastases identified in these series are attributable to either a high-risk (ie, &gt;4mm thick",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulcerated) primary tumor or more extensive regional lymph node involvement in the SLNs.",
"   </p>",
"   <p>",
"    There are no studies assessing the value of integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in patients with disease limited to a positive sentinel node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2817889\">",
"    <span class=\"h2\">",
"     Clinical stage III and local recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical locoregional melanoma (including local recurrences, satellite or in-transit disease, or clinically apparent nodal disease at presentation) (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"mobipreview.htm?7/61/8157\">",
"     table 1A",
"    </a>",
"    ) have a greater than 50 percent risk of systemic recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these patients, we obtain a complete blood count, serum LDH, and a chest x-ray for future reference. Although advanced imaging studies (CT, MRI, PET) have a relatively low yield for detecting distant metastases in asymptomatic patients, metastases are detected more frequently than in those with stage I and stage II disease, suggesting that additional imaging studies are warranted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT of the chest and abdomen &mdash; CT imaging of the chest and abdomen is commonly performed in patients with locoregional disease. While the yield for detecting distant metastases in asymptomatic patients is low, CT can often identify false-positive abnormalities and thereby function as a baseline for future studies in this high-risk population. CT of the pelvis is generally performed for patients with a locoregional recurrence below the waist, and the neck is generally imaged for a recurrence in the head and neck region.",
"      <br/>",
"      <br/>",
"      The results of body CT scans from three single-institution series in the staging work-up of asymptomatic patients with documented locoregional metastases who have a normal chest x-ray and serum LDH are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef81345 \" href=\"mobipreview.htm?22/43/23227\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. The true-positive rate for metastases ranged from 4 to 16 percent, with false-positive findings in 8 to 22 percent of studies. Pelvic CT was useful only in patients with inguinal recurrences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Brain metastases were identified in 6 percent of patients in the University of Michigan series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/23\">",
"       23",
"      </a>",
"      ], but were not observed in either of the other studies (",
"      <a class=\"graphic graphic_table graphicRef70510 \" href=\"mobipreview.htm?12/45/13019\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      PET imaging &mdash; PET may be helpful in patients with regional node disease or in-transit metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. The potential role of PET was illustrated by a prospective series of 251 patients with clinically palpable, histologically proven lymph node involvement who were evaluated with PET and CT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/24\">",
"       24",
"      </a>",
"      ]. In this series, PET and CT suggested the presence of distant metastases in 32 and 29 percent of cases, respectively. Based upon the results of imaging and subsequent verification testing, treatment was changed in 19 percent of patients. Of these, the change was due to the results of both scans in 79 percent, due exclusively to PET in 17 percent, and due exclusively to CT in 4 percent.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      &mdash;",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      is being widely used at many centers, and the role of",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      in clinical stage III melanoma is rapidly evolving [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. However, issues remain regarding the optimal technique (use of oral or intravenous contrast, respiratory gating). Like CT or PET alone, the interpretation of",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      is complicated by false-negatives, false-positives, and the identification of second primaries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15450?source=see_link&amp;anchor=H4#H4\">",
"       \"Imaging studies in melanoma\", section on 'PET/CT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other studies &mdash; Other imaging studies, such as bone scans, have not had any clinical value in asymptomatic patients with clinical stage III disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/4,5,12,14\">",
"       4,5,12,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who develop a second locoregional recurrence represent a higher risk subset and should undergo staging evaluations as if they had distant metastases, since the results will impact the advisability of attempting further surgical control of local recurrence. (See",
"    <a class=\"local\" href=\"#H2817953\">",
"     'Stage IV'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2817953\">",
"    <span class=\"h1\">",
"     STAGE IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known systemic metastases (stage IV) should be evaluated more comprehensively because the likelihood of detecting additional, unsuspected lesions is higher.",
"   </p>",
"   <p>",
"    Our approach is to stage these patients with an MRI of the brain and CT of the chest, abdomen, and usually the pelvis. CT of the pelvis is indicated for patients with a truncal melanoma that drained to the groin or regional disease in the groin or if there are symptoms suggesting metastatic involvement. Other imaging studies should be ordered on the basis of symptoms (eg, bone scan for patients with bone pain, small bowel follow-through for patients with iron-deficiency anemia). Serum LDH should be obtained in all patients as it has prognostic significance for patients with stage IV disease (",
"    <a class=\"graphic graphic_table graphicRef74203 \" href=\"mobipreview.htm?34/20/35149\">",
"     table 1B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many series report a greater sensitivity with PET scans compared to conventional radiographic studies for the detection of metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. In a series of 100 patients with stage IV disease from the Sydney Melanoma Unit, 415 metastatic lesions were evaluated with PET and routine CT scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/28\">",
"     28",
"    </a>",
"    ]. PET scan detected 93 percent of lesions. In 20 patients, PET detected 24 metastases up to six months earlier than conventional imaging or physical examination. Furthermore, the selection of surgical and medical treatment was influenced by PET findings in 22 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/28\">",
"     28",
"    </a>",
"    ]. PET without concurrent CT may complement routine imaging studies rather than replace them. In a series of 68 patients, PET detected fewer pulmonary, hepatic, and brain metastases but more lymph node and bone metastases than conventional CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    appears to be more sensitive than either PET or CT alone. In a retrospective study with 250 patients,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan detected significantly more visceral and nonvisceral metastases than either PET alone or CT alone (98.7 with",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    versus 88.8 and 69.7 percent, with PET alone and CT alone, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    was also more accurate than CT for staging regional nodes (N). Therefore, we generally complement conventional CT and MRI with integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the staging work-up of patients who have solitary or oligometastatic disease, where the issue of surgical resection is most relevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2818027\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of follow-up in patients with melanoma is to identify potentially curable locoregional recurrences and second primary cancers. The incidence of a second melanoma is increased in melanoma survivors, with the cumulative risk ranging from 2 to 5 percent at periods from 5 to 20 years after initial diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. For patients with melanoma in situ, no specific oncologic follow-up is indicated, but patients require continued dermatologic follow-up because of the risk of a second primary, particularly if atypical nevi are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk factors for the development of melanoma\", section on 'History of melanoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most initial recurrences in patients with stage I and II primary melanomas are locoregional, particularly if a SLN biopsy was not performed or not indicated (ie, for most patients with T1a primary tumors) (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). In patients who initially present with stage III disease, systemic recurrences are more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/36\">",
"     36",
"    </a>",
"    ]. Although locoregional recurrences may be curable if detected early, distant recurrences are commonly fatal. Thus, the most important elements in the follow-up of melanoma patients are the medical history and the physical examination, paying particular attention to identifying regional recurrences or second primary melanomas.",
"   </p>",
"   <p>",
"    Optimal follow-up strategy and intervals have not been determined, and there is no consensus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ]. At a minimum, patients should undergo an annual routine physical examination, including a full skin assessment and palpation of the regional lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. More frequent visits are appropriate for patients at high risk for multiple primary lesions (ie, patients with multiple clinically atypical moles, a family history of melanoma, or excessive sun exposure), or for more extensive (ie, stage II or III) disease.",
"   </p>",
"   <p>",
"    Most series that examined the value of imaging studies for routine follow-up were retrospective and showed that the majority of recurrences (80 to 90 percent) were discovered by history and physical examination and not by imaging or laboratory studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/7,40-43\">",
"     7,40-43",
"    </a>",
"    ]. Periodic chest x-rays were often obtained for early detection of pulmonary metastases. Chest x-rays and other radiographic studies detected recurrences in less than 10 percent of cases of early stage disease, but a higher percent of those with resected node-positive disease (28 percent in one German study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/42\">",
"     42",
"    </a>",
"    ]). Routine blood work including CBC, liver function tests, and LDH, were rarely the sole indicator of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/7,41\">",
"     7,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Sydney Melanoma Unit has reported the results of a prospective study, which assessed the value of follow-up surveillance studies in 211 patients who had relapsed after initial treatment for a stage I, II, or III melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/44\">",
"     44",
"    </a>",
"    ]. The first melanoma recurrence was local in 13 percent, in-transit in 17 percent, in regional nodes in 46 percent, and distant in 24 percent of the patients. Seventy-three percent of all recurrences were detected by the patient. The presence of a symptom was the only independent predictor of a patient-detected recurrence. There was no statistically significant difference in survival depending upon whether the recurrence was detected by the patient or the doctor. The authors of the study concluded that better patient education may improve the rate of detection and that more frequent follow-up visits are unlikely to be valuable.",
"   </p>",
"   <p>",
"    In a subsequent study from the same group, 108 patients with positive sentinel lymph node biopsies were followed with surveillance chest x-rays every six months for five years and then annually for an additional five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/45\">",
"     45",
"    </a>",
"    ]. Lung metastases were eventually detected in 23 cases (21 percent), but the surveillance chest x-rays detected only 11 of these, only three of whom were candidates for metastasectomy. In addition, false positive findings were identified in the lung in 19 cases. The authors concluded that serial surveillance chest x-ray were unlikely to be beneficial.",
"   </p>",
"   <p>",
"    In conclusion, the major value of the follow-up visits is to detect potentially curable recurrence, particularly locoregional. The value of imaging studies in the routine follow-up of patients with stage I to III is highly questionable. Thus, at a minimum, we recommend a detailed medical history and physical examination with special attention to regional recurrences every three to 12 months, depending on the risk of recurrence. Patients should be informed that the value of imaging studies and blood work is of questionable relevance in an asymptomatic patient. Nonetheless, CT and MRI, more recently complemented or replaced by",
"    <span class=\"nowrap\">",
"     PET/CT,",
"    </span>",
"    is often a component of the overall follow-up for patients with stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    melanoma. Additional studies are needed to define the role of imaging in the follow-up of the melanoma patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2818059\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests and imaging studies are necessary to accurately stage patients with melanoma prior to definitive treatment and for follow-up after initial therapy. The specific studies are a function of the clinical setting:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2818066\">",
"    <span class=\"h2\">",
"     Clinical stages I and II",
"    </span>",
"   </p>",
"   <p>",
"    The indications for lymphatic mapping sentinel lymph node (SLN) biopsy in patients with clinical stage I and II disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGE III DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage III disease include those with clinical stage I or II disease, in whom occult lymph node disease is diagnosed at sentinel lymph node (SLN) biopsy, and those with clinical stage III disease, based upon the presence of clinically palpable nodes (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). Patients with other forms of lymphatic regional metastases (satellite lesions, in transit metastases) are also classified as stage III.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Positive sentinel lymph node",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common utilization of SLN biopsy in patients with a clinical stage I or II melanoma identifies a subset of patients with clinically occult, pathologically positive SLNs (stage III) who are at increased risk for the subsequent development of disseminated disease compared to otherwise similar patients whose SLNs are negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with positive SLNs often undergo comprehensive imaging studies either before completion lymphadenectomy or following surgery when they are being considered for adjuvant therapy or participation in adjuvant therapy trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link&amp;anchor=H2#H2\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Prognostic factors affecting staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the frequent use of such studies, routine staging with CT, magnetic resonance imaging (MRI), or PET does not appear to be useful in this setting.",
"   </p>",
"   <p>",
"    The low frequency of detectable metastases found with extensive imaging is illustrated by three large single institution series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series from M. D. Anderson Cancer Center (MDACC), 314 patients with a positive SLN were evaluated, of whom 270 underwent CT of the chest and abdomen and either CT or MRI of the head [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/17\">",
"       17",
"      </a>",
"      ]. Occult metastases were confirmed in five patients (1.9 percent), nearly all of whom had significant tumor burden in the sentinel node and ulcerated primary tumors. Routine screening identified second primary tumors in 10 patients (3.7 percent), and the false positive rate was 12 percent.",
"     </li>",
"     <li>",
"      In a report from the University of California at San Francisco, CT of the chest, abdomen, and pelvis detected metastases in one of 185 patients (0.5 percent) with a positive SLN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/18\">",
"       18",
"      </a>",
"      ]. This patient had an ulcerated primary lesion that was &gt;4 mm thick as well as extensive involvement in the sentinel lymph node. No brain metastases were identified in 112 patients studied with either MRI or CT.",
"     </li>",
"     <li>",
"      In a series from Memorial Sloan Kettering Cancer Center (MSKCC), 4 of 107 (3.7 percent) patients with positive SLNS had distant metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/19\">",
"       19",
"      </a>",
"      ]. All four had thick primary tumors and a significant tumor burden within the SLN. The role of PET was evaluated in this series, with results similar to CT alone. If body CT scans and PET had been restricted to patients with thick primaries, the true positive rate would have been 13 percent; if CT and PET were restricted to patients with both thick primaries and macrometastases in the sentinel node, the true positive rate would have been 16 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, most of the occult distant metastases identified in these series are attributable to either a high-risk (ie, &gt;4mm thick",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulcerated) primary tumor or more extensive regional lymph node involvement in the SLNs.",
"   </p>",
"   <p>",
"    There are no studies assessing the value of integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in patients with disease limited to a positive sentinel node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical stage III and local recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical locoregional melanoma (including local recurrences, satellite or in-transit disease, or clinically apparent nodal disease at presentation) (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"mobipreview.htm?7/61/8157\">",
"     table 1A",
"    </a>",
"    ) have a greater than 50 percent risk of systemic recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these patients, we obtain a complete blood count, serum LDH, and a chest x-ray for future reference. Although advanced imaging studies (CT, MRI, PET) have a relatively low yield for detecting distant metastases in asymptomatic patients, metastases are detected more frequently than in those with stage I and stage II disease, suggesting that additional imaging studies are warranted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT of the chest and abdomen &ndash; CT imaging of the chest and abdomen is commonly performed in patients with locoregional disease. While the yield for detecting distant metastases in asymptomatic patients is low, CT can often identify false-positive abnormalities and thereby function as a baseline for future studies in this high-risk population. CT of the pelvis is generally performed for patients with a locoregional recurrence below the waist, and the neck is generally imaged for a recurrence in the head and neck region.",
"      <br/>",
"      <br/>",
"      The results of body CT scans from three single-institution series in the staging work-up of asymptomatic patients with documented locoregional metastases who have a normal chest x-ray and serum LDH are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef81345 \" href=\"mobipreview.htm?22/43/23227\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. The true-positive rate for metastases ranged from 4 to 16 percent, with false-positive findings in 8 to 22 percent of studies. Pelvic CT was useful only in patients with inguinal recurrences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Brain metastases were identified in 6 percent of patients in the University of Michigan series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/23\">",
"       23",
"      </a>",
"      ], but were not observed in either of the other studies (",
"      <a class=\"graphic graphic_table graphicRef70510 \" href=\"mobipreview.htm?12/45/13019\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      PET imaging &ndash; PET may be helpful in patients with regional node disease or in-transit metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. The potential role of PET was illustrated by a prospective series of 251 patients with clinically palpable, histologically proven lymph node involvement who were evaluated with PET and CT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/24\">",
"       24",
"      </a>",
"      ]. In this series, PET and CT suggested the presence of distant metastases in 32 and 29 percent of cases, respectively. Based upon the results of imaging and subsequent verification testing, treatment was changed in 19 percent of patients. Of these, the change was due to the results of both scans in 79 percent, due exclusively to PET in 17 percent, and due exclusively to CT in 4 percent.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      &ndash;",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      is being widely used at many centers, and the role of",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      in clinical stage III melanoma is rapidly evolving [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. However, issues remain regarding the optimal technique (use of oral or intravenous contrast, respiratory gating). Like CT or PET alone, the interpretation of",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      is complicated by false-negatives, false-positives, and the identification of second primaries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15450?source=see_link&amp;anchor=H4#H4\">",
"       \"Imaging studies in melanoma\", section on 'PET/CT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other studies &ndash; Other imaging studies, such as bone scans, have not had any clinical value in asymptomatic patients with clinical stage III disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/4,5,12,14\">",
"       4,5,12,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who develop a second locoregional recurrence represent a higher risk subset and should undergo staging evaluations as if they had distant metastases, since the results will impact the advisability of attempting further surgical control of local recurrence. (See",
"    <a class=\"local\" href=\"#H2817953\">",
"     'Stage IV'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STAGE IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known systemic metastases (stage IV) should be evaluated more comprehensively because the likelihood of detecting additional, unsuspected lesions is higher.",
"   </p>",
"   <p>",
"    Our approach is to stage these patients with an MRI of the brain and CT of the chest, abdomen, and usually the pelvis. CT of the pelvis is indicated for patients with a truncal melanoma that drained to the groin or regional disease in the groin or if there are symptoms suggesting metastatic involvement. Other imaging studies should be ordered on the basis of symptoms (eg, bone scan for patients with bone pain, small bowel follow-through for patients with iron-deficiency anemia). Serum LDH should be obtained in all patients as it has prognostic significance for patients with stage IV disease (",
"    <a class=\"graphic graphic_table graphicRef74203 \" href=\"mobipreview.htm?34/20/35149\">",
"     table 1B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many series report a greater sensitivity with PET scans compared to conventional radiographic studies for the detection of metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. In a series of 100 patients with stage IV disease from the Sydney Melanoma Unit, 415 metastatic lesions were evaluated with PET and routine CT scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/28\">",
"     28",
"    </a>",
"    ]. PET scan detected 93 percent of lesions. In 20 patients, PET detected 24 metastases up to six months earlier than conventional imaging or physical examination. Furthermore, the selection of surgical and medical treatment was influenced by PET findings in 22 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/28\">",
"     28",
"    </a>",
"    ]. PET without concurrent CT may complement routine imaging studies rather than replace them. In a series of 68 patients, PET detected fewer pulmonary, hepatic, and brain metastases but more lymph node and bone metastases than conventional CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    appears to be more sensitive than either PET or CT alone. In a retrospective study with 250 patients,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan detected significantly more visceral and nonvisceral metastases than either PET alone or CT alone (98.7 with",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    versus 88.8 and 69.7 percent, with PET alone and CT alone, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    was also more accurate than CT for staging regional nodes (N). Therefore, we generally complement conventional CT and MRI with integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the staging work-up of patients who have solitary or oligometastatic disease, where the issue of surgical resection is most relevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of follow-up in patients with melanoma is to identify potentially curable locoregional recurrences and second primary cancers. The incidence of a second melanoma is increased in melanoma survivors, with the cumulative risk ranging from 2 to 5 percent at periods from 5 to 20 years after initial diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. For patients with melanoma in situ, no specific oncologic follow-up is indicated, but patients require continued dermatologic follow-up because of the risk of a second primary, particularly if atypical nevi are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk factors for the development of melanoma\", section on 'History of melanoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most initial recurrences in patients with stage I and II primary melanomas are locoregional, particularly if a SLN biopsy was not performed or not indicated (ie, for most patients with T1a primary tumors) (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). In patients who initially present with stage III disease, systemic recurrences are more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/36\">",
"     36",
"    </a>",
"    ]. Although locoregional recurrences may be curable if detected early, distant recurrences are commonly fatal. Thus, the most important elements in the follow-up of melanoma patients are the medical history and the physical examination, paying particular attention to identifying regional recurrences or second primary melanomas.",
"   </p>",
"   <p>",
"    Optimal follow-up strategy and intervals have not been determined, and there is no consensus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ]. At a minimum, patients should undergo an annual routine physical examination, including a full skin assessment and palpation of the regional lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. More frequent visits are appropriate for patients at high risk for multiple primary lesions (ie, patients with multiple clinically atypical moles, a family history of melanoma, or excessive sun exposure), or for more extensive (ie, stage II or III) disease.",
"   </p>",
"   <p>",
"    Most series that examined the value of imaging studies for routine follow-up were retrospective and showed that the majority of recurrences (80 to 90 percent) were discovered by history and physical examination and not by imaging or laboratory studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/7,40-43\">",
"     7,40-43",
"    </a>",
"    ]. Periodic chest x-rays were often obtained for early detection of pulmonary metastases. Chest x-rays and other radiographic studies detected recurrences in less than 10 percent of cases of early stage disease, but a higher percent of those with resected node-positive disease (28 percent in one German study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/42\">",
"     42",
"    </a>",
"    ]). Routine blood work including CBC, liver function tests, and LDH, were rarely the sole indicator of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/7,41\">",
"     7,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Sydney Melanoma Unit has reported the results of a prospective study, which assessed the value of follow-up surveillance studies in 211 patients who had relapsed after initial treatment for a stage I, II, or III melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/44\">",
"     44",
"    </a>",
"    ]. The first melanoma recurrence was local in 13 percent, in-transit in 17 percent, in regional nodes in 46 percent, and distant in 24 percent of the patients. Seventy-three percent of all recurrences were detected by the patient. The presence of a symptom was the only independent predictor of a patient-detected recurrence. There was no statistically significant difference in survival depending upon whether the recurrence was detected by the patient or the doctor. The authors of the study concluded that better patient education may improve the rate of detection and that more frequent follow-up visits are unlikely to be valuable.",
"   </p>",
"   <p>",
"    In a subsequent study from the same group, 108 patients with positive sentinel lymph node biopsies were followed with surveillance chest x-rays every six months for five years and then annually for an additional five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/15/35065/abstract/45\">",
"     45",
"    </a>",
"    ]. Lung metastases were eventually detected in 23 cases (21 percent), but the surveillance chest x-rays detected only 11 of these, only three of whom were candidates for metastasectomy. In addition, false positive findings were identified in the lung in 19 cases. The authors concluded that serial surveillance chest x-ray were unlikely to be beneficial.",
"   </p>",
"   <p>",
"    In conclusion, the major value of the follow-up visits is to detect potentially curable recurrence, particularly locoregional. The value of imaging studies in the routine follow-up of patients with stage I to III is highly questionable. Thus, at a minimum, we recommend a detailed medical history and physical examination with special attention to regional recurrences every three to 12 months, depending on the risk of recurrence. Patients should be informed that the value of imaging studies and blood work is of questionable relevance in an asymptomatic patient. Nonetheless, CT and MRI, more recently complemented or replaced by",
"    <span class=\"nowrap\">",
"     PET/CT,",
"    </span>",
"    is often a component of the overall follow-up for patients with stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    melanoma. Additional studies are needed to define the role of imaging in the follow-up of the melanoma patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests and imaging studies are necessary to accurately stage patients with melanoma prior to definitive treatment and for follow-up after initial therapy. The specific studies are a function of the clinical setting:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical stages I and II",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic patients with localized stage I or II primary melanoma, we recommend not doing extensive imaging studies (CT, PET,",
"      <span class=\"nowrap\">",
"       PET/CT)",
"      </span>",
"      since the yield is extremely low and the false positive rate is unacceptably high (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical stage I and II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom the regional lymph nodes are clinically negative and the primary melanoma has a low risk of recurrence, we recommend not performing lymphatic mapping with sentinel lymph node (SLN) biopsy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link&amp;anchor=H17#H17\">",
"       \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Patient selection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with clinically negative nodes and a primary melanoma at intermediate or high risk for lymph node metastasis, we recommend lymphatic mapping with SLN biopsy for staging purposes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link&amp;anchor=H17#H17\">",
"       \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Patient selection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Positive SLNs (pathologic stage III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a positive SLN (pathologic stage III), the extent of further staging work-up is influenced by the degree of SLN involvement and the risk associated with the primary tumor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients at low risk of disseminated disease (ie, limited involvement of the SLN, nonulcerated thin or intermediate thickness primary tumor) in whom the only evidence of stage III disease is a positive SLN, we suggest not performing body CT or brain neuroimaging prior to completion lymphadenectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). More extensive imaging may be appropriate if adjuvant therapy or participation in a clinical trial is being considered. (See",
"      <a class=\"local\" href=\"#H2817844\">",
"       'Positive sentinel lymph node'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a positive SLN and a thick or ulcerated primary tumor or with a significant tumor burden in the SLN are at higher risk of disseminated metastases. For this group, we suggest more comprehensive imaging (ie, body CT with or without MRI of the brain) prior to the completion lymphadenectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2817844\">",
"       'Positive sentinel lymph node'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Positive findings on imaging studies should be interpreted cautiously because of the high false positive rate. Unless there is unequivocal evidence of metastatic disease, a biopsy should be performed prior to treating the patient for disseminated disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical stage III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who present with clinical evidence of regional involvement or who develop an initial locoregional recurrence, we obtain a complete blood count, serum LDH, and a chest x-ray for future reference.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest CT imaging of the chest, abdomen, and pelvis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although the yield of these tests is low, they often identify false-positive abnormalities and thereby function as an important baseline for future studies in this high-risk population. The neck is generally imaged for primary lesions in the head and neck region. (See",
"      <a class=\"local\" href=\"#H2817889\">",
"       'Clinical stage III and local recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with advanced regional disease for whom surgery is being considered, we recommend obtaining a",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan, as the yield is higher than with CT alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2817889\">",
"       'Clinical stage III and local recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not imaging the brain (CT, MRI) in asymptomatic patients with stage III disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2817889\">",
"       'Clinical stage III and local recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who develop a second or subsequent locoregional recurrence represent a high risk subset and should undergo staging evaluations as if they had distant metastases. (See",
"      <a class=\"local\" href=\"#H2817953\">",
"       'Stage IV'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Stage IV disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stage IV disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with stage IV disease be evaluated with MRI of the brain and CT of the chest and abdomen, including the pelvis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition, CT of the pelvis is indicated for patients with a history of disease below the waist or if there are suggestive symptoms. Other imaging studies should be ordered on the basis of symptoms (eg, bone scan for patients with bone pain, small bowel follow-through for patients with iron-deficiency anemia). (See",
"      <a class=\"local\" href=\"#H2817953\">",
"       'Stage IV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a single site of distant disease or presumed oligometastatic disease who are being considered for surgical resection, we recommend a",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan to complement conventional imaging studies (MRI of the brain and CT of the chest and abdomen and pelvis) prior to surgery to exclude other sites of metastases (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surveillance after local treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of follow-up in patients who have undergone definitive treatment for a primary melanoma is to identify potentially curable recurrences and second primary cancers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We typically perform a routine physical examination, including a full skin assessment and palpation of the regional lymph nodes, which should be repeated at least yearly. The frequency of such evaluation should be increased in patients at high risk of recurrence. Imaging studies should be done if symptoms are present; the value of routine imaging is uncertain. (See",
"      <a class=\"local\" href=\"#H2818027\">",
"       'Surveillance after treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/1\">",
"      Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998; 134:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/2\">",
"      Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/3\">",
"      Zartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 1987; 35:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/4\">",
"      Ardizzoni A, Grimaldi A, Repetto L, et al. Stage I-II melanoma: the value of metastatic work-up. Oncology 1987; 44:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/5\">",
"      Khansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989; 124:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/6\">",
"      Iscoe N, Kersey P, Gapski J, et al. Predictive value of staging investigations in patients with clinical stage I malignant melanoma. Plast Reconstr Surg 1987; 80:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/7\">",
"      Bass&egrave;res N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995; 191:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/8\">",
"      Bastiaannet E, Oyen WJ, Meijer S, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006; 93:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/9\">",
"      Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005; 104:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/10\">",
"      Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/11\">",
"      Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/12\">",
"      Roth JA, Eilber FR, Bennett LR, Morton DL. Radionuclide photoscanning. Usefulness in preoperative evaluation of melanoma patients. Arch Surg 1975; 110:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/13\">",
"      Meyer JE, Stolbach L. Pretreatment radiographic evaluation of patients with malignant melanoma. Cancer 1978; 42:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/14\">",
"      Thomas JH, Panoussopoulous D, Liesmann GE, et al. Scintiscans in the evaluation of patients with malignant melanomas. Surg Gynecol Obstet 1979; 149:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/15\">",
"      Au FC, Maier WP, Malmud LS, et al. Preoperative nuclear scans in patients with melanoma. Cancer 1984; 53:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/16\">",
"      Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011; 364:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/17\">",
"      Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006; 24:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/18\">",
"      Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/19\">",
"      Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007; 14:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/20\">",
"      Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/21\">",
"      Buzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/22\">",
"      Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/23\">",
"      Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997; 4:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/24\">",
"      Bastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009; 27:4774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/25\">",
"      Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/26\">",
"      Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oncol Clin N Am 2007; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/27\">",
"      Bronstein Y, Ng CS, Rohren E, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol 2012; 198:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/28\">",
"      Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/29\">",
"      Dietlein M, Krug B, Groth W, et al. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 1999; 20:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/30\">",
"      Holder WD Jr, White RL Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/31\">",
"      Steinert HC, Huch B&ouml;ni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/32\">",
"      Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/33\">",
"      Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/34\">",
"      DiFronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 1999; 6:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/35\">",
"      Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/36\">",
"      Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010; 28:3042.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/38\">",
"      Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008; 95:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/39\">",
"      Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/40\">",
"      Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995; 221:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/41\">",
"      Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/42\">",
"      Garbe C, Paul A, Kohler-Sp&auml;th H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/43\">",
"      Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/44\">",
"      Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/15/35065/abstract/45\">",
"      Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 2009; 16:571.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7621 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35065=[""].join("\n");
var outline_f34_15_35065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2818059\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL STAGE I AND II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2817837\">",
"      STAGE III DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2817844\">",
"      Positive sentinel lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2817889\">",
"      Clinical stage III and local recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2817953\">",
"      STAGE IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2818027\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2818059\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2818066\">",
"      Clinical stages I and II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGE III DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Positive sentinel lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical stage III and local recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STAGE IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical stages I and II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Positive SLNs (pathologic stage III)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical stage III disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stage IV disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surveillance after local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7621|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23227\" title=\"table 2\">",
"      Body CT in stage III melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/45/13019\" title=\"table 3\">",
"      Brain CT in stage III melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15450?source=related_link\">",
"      Imaging studies in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_15_35066="Spina bifida A";
var content_f34_15_35066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78078%7EOBGYN%2F58063%7EOBGYN%2F68832%7EOBGYN%2F77490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78078%7EOBGYN%2F58063%7EOBGYN%2F68832%7EOBGYN%2F77490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal view showing the large lumbo-sacral defect. There kyphoscoliosis over the area of the defect with total disruption of the normal spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view showing the U-shaped vertebral body with the neural tissue protruding through.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal view of the fetal head demonstrating the dilated posterior horns of the lateral ventricle in addition to the small cerebellum. The cisterna magna is not seen since the herniating cerebellum has obliterated it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAWsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDD0H4dXOq6zpkupWKJZrbSmeG9uHtGYpjGSoLIBuB3YwcVun4fv4rtdObwjJpdloenSzJse4uJWllY5dgzoMp0wQMEc5NdPY3+k3OlDSbjxY0siJKkmpTIVcbmVguJchuPlwcgiug8KahaWC38d14nh1SWWYyQ+YYYndAgA2qmAAcHtxQB5inwo1TQB9tvNS0wRRO/lFWlZuf4QoUk8elafxB8OXV1pnhPV9OjE8NhE3214srtRuAcMA2M+2RXoPiHWRd6NaT6fcW8V0r/AL2EXcYmiDLghGLBfMGeOcVHp179p0l4bWGNZUhaaO2nmSZiQWG2XYSCScHrQB4j4d8NaqnxEl0e6tZI797TzljZ1DbeCpJJwOoyPet7xfZSyeGIZrq80+xVrh0/0q4IOQSG4VWwAc89OKTTbiDVPjH9qk1CCFdPtYXlmkZtobytjxk46hj/AOOmtTSmuJdNhijhlvNGuxcJetpro00hWWQiHazKRE+/JbrwBxzQBy3/AAqTxpNptoI00t1Qq6vHfqVZfUHHNc5428Baquo2lld3uiWuoo3lrBNqSKxDkbAPc19OaXcJp+kaTZvHuYRrC3kujrb7U/jIbgcYzzziuc8QWsb+KftFgnig6i7wsrWZDaezAgZfPGNuck/zxQB8d6jpd5p2rX1hcgJd2btHKFcMMjrhhwfrT7Kx+2ae0qbjNGcN83AHPP8AKum8eyCHx1rE7EBZLuZG6cMGPFc/4d1FLDUJXlUm1mUwyD0z0P1oAWOaRNPaOP76YRtvQgjin2tvJ/Yq30Ehyr+W67ugJxmprKI75odjfOu0E9yD3/Sk0q3uWguEIaOB22yov8JHcflQBPpdqmm3O65bfIHzEezAjoa34fsl/G0cBdfPXcEbrHIOCP8AdPT61zN0jmCYvJsltyHQhs5xjJH4VYtdWFjL57BdwYMFB6+uPqOaANBrYwSI80z+ShAyDzj0P0rsb2PRrnQ447OREuipB2nGVPIPPvXCrrKtdXsMm37NdZaIgZ2564/wqNBHG0CQv5ihSoIJ3Bweh9RQB1UFzHFp3n3YP9ow3GORwRj09KbeatKsRiMpS5JVmhJ4ZM4IyO2PzxXO3UM1zKsE7PEvm8DJ+8eoBq/FpyQTx589ZtnltvH+rlB4HPY9qALEcsF1dySpcMkjO2wBsFUwQMDvjrXW+E50h097yGaVtSj8s3EBkMayp2lTPFcsjQTSyqdPnjld13rGmRjqWGOc54+lbiWj3l/bx3EaLFOoNukSENz79CMjlT79KAPYbCxtLq4W9htpGLx+dvh5ZVHRh2xwQRWtcajp1w1skl5bo5gMkM8OU3YOSjr615b4b1yTT1awudsV5G3lvGiEqyg5GBkeuMZxXTSa9NJ9meHT7e4vnkY/ZViClEXqwbp09DzmgC54s8B6L44uJEu/Jtb+VEeDUrYszFgPu5bAZRn7p575r508YfDvxH4WV57+xlfT9xCXcJ3owBPJxyp74P519L6RIrM8ryvZwySbnhckbDj0HTPHQ1radqM7FkuzE1ntIZpG3xupJHPB2uBjg8etAHxACcfK5wfQ0hzjknjt6V9h6x4D8LeIluLiTT9NvJ45S++KQxvKp67mTG7oKwT8B/C95e3Bt/7ehj2+YI/tESrGTztG5SSPQ5PvQB8uJvJyC+cZ4p9vDLPMsMQd5XO1Y0BZj7ADmvqzS/gh4Shsy8un6ldXCkSPLeXuxET0BjUK3Tp1rudL0nTNA1O2sdG0XTraKRWl822gWFih5OHbLYJ96APAPAnwS1S78vUPGckmj6WGBMO//SZQQMYxkKM468+1fQGg6NZ6NaR6Z4ft4LC3t4zIsaEu8n1bu5xnJzVzUtNW6sj9r1K3kwd8MUTFtzde4yQPem3GpGw0i3lZbeMIBl1f51A43hRwAcnrQBz97qLRyI9xL9mLnzIHdsEqAMkjkls564FY934htV1dhFNM8iAzRwvJgS/Ue55/KodT1O2nsb9VsjfQyBkBTBIzx8+cYrjtXWXSb22SFY0Dw+UbuWMEkkc8j06UAW/FnjS7jmitbOG0hvHX51Db0TPO447+gqrYePpdOnhkubJEuYozgSylgeeWA+vSvN9St4BqE7SThoSQC0bfex2AH4VlXV+oO4x+a+3aoUkjntg9KAPbbj4iadqWlNbLayO88qtNHsOXb65+6K5jWtZgurlZIgVukmVbdBkBQeXZh6dh9K8+ttcSzvLaZIQohjCRCTkEg8n65rMv9Xma4kuUbBmZyRk8knqaAOj8RX8MlxM9gzSS3ch82QvgY9vas6LSJHkjvYyHGdsajuR1P6Vz0uotKkMWAkaoUznGc9zXQ+Gtdgs5x5sryrHH5aDGASerYoAfrtreQ+TPcWqol13yDjA6Vx90NjAqCFIyOtehanrM3iLU7ZVQJZ25EMC/32P3ifpWT4itoFuLmG1cO0SE/Lz8xNAHFFj6g0ZOOTVj7K4tvM/EjHb1qr1OKAFLH1oDc9TTPrR9Dx70Ad94WaIaPcPhS8Vs/wCZNdvoj3MWk2scltbsyoBlgMmvJtBvWMIs4ySZ5AGyO2a9DvPEP+kutusJiT5FOOwGP6UAdjoCTW/xLMMDkSNbTGEEj/WbD5ZUH+LPSuv8F2/iV9Vsp/G0d02pxQTJbm4jjN0QWHI9e+PbOK8s1nVVnutH1CQEFv3EpyAQegOR05A5roPBjyNHrMAkeS5gmLRlpGLYK5GCefYUAdZ8ULOabQ7+Od5ZroWy3Mf2qCNZlKMfvbeuex9MVJ8DrqNl1FreJ8PHDuWNMlSd3JHp715w/iG41a+WK1LNczo8DhjktgdqZ4aubiNpVt7maxm2ruEchjIdT/F6jOePrQB6ugsrL4pave6tfwQahcC3hslu4Cd8fGdgUYLZwvPavHPiTYW118QZ7e2liuJNxDOiFQ2cjH1FUvHPi651C7+1iaVLy2dTvVvmVhwQD6ZAI/CuQ0zVb2bxGt5HM8lweSGOS9AFyNYf7Pa3m/dTeYVyTySOn68VjahdHEkYLJIpwdrHmvQ/iJoS3Cw6npaBUmjEkkeOjE8/ka82ntyl+RcMNz8gjp6c0AU3nYxBGyyh89f6111jo8c95HbKFJmh3qcdRjg/0rnlhW3gnWT5kcfKR/Catafq01q9lL83mWbbcnoVJ/lQB0tglpapBBqG1ZZIypc8bXB4z/ntWbqWosglhVRI0rHLDuar63Kl9cySjdGHAPHRW6/lVayd3WSG7P3ZOZcDMZPc+xoAi2TpdRyM7FJFJOOh9RVlrO3kgJb5ju3IR0IHUVoWcMn2i5LqJRG+4oDyeB8w9ev5V0tv4auDM8ZSO3kmxPaqw+SQ45UHsf8AGgDFtNEivbuCKyeMmfG1O8TkZGR6Z4rs9B8FNcagLe7tXhO3GWHAlHQ/1FbWkabp+qaZZmDTTBqajIlC7WQj+L0bBHSvQ/D2kX12vl6hMhnIUPPEvDqT8rexHrQBgaP8O1vY2tb0RJfKCu7HBbqp/HtW03hGGz0iO51NEmtVOydnXMkZHHzHvg9+tbtt4f1aC6M91qe64jlGCo27k7Ej+vvV+5eC61QwXV48A4Z43+VX9Qw9ffvQBz1p4Q8OkW9xFeM8xbcJkTcJF/21Hpnn862Y7fRfs0cFvDp93cO/lzNFkPGem5M9Dx071Lo95pVtfNbW7wxyRSt5QA3KEHGTjocelWbWy0GTUJp2dbaV2xE28YZjzlT0YexoApWtvoDyzpI0Snbsb7bbqpcnpz61T1TwvpTaVPKouI08wKhtX+ZTjkbh0Ga6LV7HSoIvtDXEdteMuTPsDZOOm09vUVDYaY0BeeOOZdkSxv5Eu0eXjO9F6ZB6igDldO0uXebW0vvNmb5f9JUFy2Ojdwf8Ktf8I3b2zxi0IO5DFcxRSvEV+oPUjvk10l9pwaQXGmWl2buYKq3ExBUgfxcHn8RS6RbNPc3c0RkWUkC7jtwwV+xZST1+o7UAcJeebZypp62E0UKvsK2DnaR2du4H04NXdQvbo2NkjXUs1jB92D7jEYwTyMkfjXZW0MGn6jHbReRdy3DEeQrEGMf3gecY9KiutOneaQT2bCAI0MpQKkbgn7ynqfpigDnIbx9YtlS0v4REoZYoLhf3cee+3qGHNOuNSXT7nzNSvvt0nliENHnZt9N4qgfD4tLuOLTtNmW05ZAZQjv23MRjvz+lWUlitZLe3i0jT0VIys0iTGRie+do2qPrQAklzqtxdefbaMqwpEY4hcNgbfXAAOD2rOimuIdNuodRUIZDuWGJRnrgBhncfYVZuNVi/s0LOEthKxZpBIweMZ4B7ntgVhzWslzdrd2P9pXMVvGP3m0RIVPO7A+8RnpQBjapqU2nWF1aPY7Zbxy0zSPtz+XLHHYcVw3izVLjUI4hcqUt1iwIwjbF9gT1PH616ZqWoQX1qkFwjSLESJXjgeM7cdCTySfas6bTdP1uwWa4knFvEhC+acMR7ADOPUnrQB4bdOyGEoGIkHyqRhFyefrzWbqNlNaXS29wBuUgmQZ4ya9EvtJC3bzWttKLIsIwZo9u4DqRu4qrrdkbOylVrWQGdxtYoeV9B7cdaAPOr24Yq6Y8xFO1S/BB+lUCxOAT0966fxLoTaey5yDIu7YOuSeAPWsRNLu22H7NMfMBK/IecdfwoAon/PNSW7lZFZcbwQaJYHiOJFK545FR7cfWgC+NTuIkQRsFKE4wfXvVzSb7LzvPJlmXOGPfHasPkk5xke1Pt5BFMjlcqpyR60AbF5G1vEbXlp5doAHYdTWaYRgk8vkjbVqLUhLevczYO1flBosWjzNOy9ARHH6saAMp1KnBzxxQgJBP6ZqbywZWEvytnBFCQtkBFJxyfpQBd0YsjNMMhk79AK6XTLW7lso33N8xJ4XPc1zAPl6S2wEySvncOeBXa6XO0GnwRsqBlXkGgC/rUStDqllHgeUyzoCOnPI+lWfDeqXsGuWt9at5g4hulI5bA64+lXrq3C3qy3AzLtMbnqHjI61j+FZ2t9Yu40Bdk/eKox8209PyoA7OfS4bPVjd20aB4LlL2PAPzRP1+uDkY+lVPiTa/Yry61PTuI5VErY5xuHP6jNdZ4jniFlp+pW5JjeLAyccHqPrXEWeqW2qz39nO4+zT222IjIw3OB+dAHlVzcmaVpfvJP1z0z707QVFprSSA4eM7l4zkUiRJClxHMOm5BnnDZ/+tVeGbiFmJE8B646igD0rW9UDW0S25Uj5o8AdMjjNcTfWyy3NwuQGeISLzn5u9Rm8FxEfLdo2dgMY44HBH+e9Jezu0sBWRQ2ArsRjB6fkaAMuQtEoVzuVzyPp3qxFukZmjAZAAiqRjIPal/s95GcMdroxJQ+nXg/StnRrcXM8lm7IoKq9uzd2/u/zoABp1zHpm6BN4IK+VIMspB/l7Vp6Xpn2pRcW7xrcqNk0THJ29Bx364NS+bcTwTxFz9qtWG6M/ewDwVPt6VbXULF7h5JEAnK5LDOVY9SPY8UAdDpttZQ6fHdG1WNyvySRtkDjB/r9R9Kkv8Axbbw6ZbqxjlMUmCo43J3KnsR1rza01+RnktWYeQwbeuP4v7w9O1ZVzPIpRiR1Bye56H8KAPVtR8diw+x3WmMqmSXIWUYBbAySO2R6VrWnxM1DTLuO43RpbPnzLfYGKZ9P9k14k927qsNwMpEScein+eKbdXUo8tkkyEG0MBkbaAPd7r4u6pNeG2WWCG3cHy5HAyvH3W9D/OuW1/x5f3uprcz5liWPy5UJKFXHcEdAa8qu7uebyi+x2x988h/qPWnyzq9uu3elwCBgtkH296APRn8T3KG3jspzCJj5xkkfdsbn5Sa0oPFlxqQS3nn2XcMoaFWGBvHUBh0zXmFr9tuU+YYjRTuJAzj39RViCSeW2mhd4/LQ4wvBI7EUAe32fjm9u2t7G+k8m6jIIkKhxIuf4gO3vXR3Hiu/wBDDeRfn7NL94WqLJg+jIegPqK+ebTVJbWKKOIEHdywAbj1z3re0PWp9HuLkneqSR8OkfmLz6j0z/KgD3DSPiLb3LW0Vw5hLozR5VsWuOMqM5P8q6228dadea1FJOU2eUY1nPyM554I/i9a+cbLWpbfUBcRqLa+kG1jDGZVkXvwckZ4qbS7lrPU0ZPtTNv3KjLhFY+xHSgD6EtdS06TUXnMiwqGbF3bDaQ46ZBPy8cGumtbkSSi9NpdysCBGoHm7yf4zg4xx1NfPmn+MPsd75V9HHDDI6lltwPMyO47dfUV2Fz4yJuI1t9bubIlM/Z7hAgZccfMO9AHpd7eQ311PbajcSLHG6tEikRIW7hz6U7Tdc0OOyvLRPMFvbn97MY8K4J4APce9eZr4nlt7KZNVuZIAB5YlSQPuB5HBXLfzp+j+Nr/AE22tLSae1mJ5ispowSv+2SOPfk8UAdFHpHhrU9dtommmuNPkTEiEkF2GSCfRB69625PB+mNcvBb3cmGX91EXO1EB9Rz1rhLzx3fxa2sirZO5AV1WAkLnqcjrj8qrXPjWRL/AO2313HFkeWBGACydsDPB5oA9IbQYox/ocvmNu2sZGLHnsPQVijwlbQNcx2KRzgufNVFEZQ4yWYn73sM4rg9P+JNo2rN9kkCTyHyolVSApHck/eaulbx1BFJBEkV1fy5O5RnAI55/GgCpfaZPDp63eo2NuU8wi3Nw3IPYf8A1hXCeKtKuriHypYry6u5SJJZSCI0A6AAdBnt+degW/iQeMLiWNPMjuRhJTIu1IV/uqOcsfX+VaGq6zYaWZLa4voVhjTMoC8InTlug6dKAPD9Z0CCxuFvdQea4UqDHGOpP9BXZeDZ9PvrfZcxPvZQshGFKR/3QO2en5mqc+qRXt9B/Yen7oiGMXnSYVj2Zu+PaqH2O4F1NeTsosIZwXMIA81x1A9s0AaHxG+H76oILrSrBAsgKxxK2AEx19gP1rxHxF4euNKdg9vJGsQ2yMxz81fW+g+IJZdPkn1GJLdpAIolJycY6AewrzD4320c+i24tkKRhzIcjDMMHk/U0AfO3OeaaenGcVYuIWhIWRdhKg8+hqHbgHI49KAGDPvzVq1kKzxYG7aflHqarY7qP1p8b+WVYZ3dvagDZhsDPf8AyDeVG+QnsOpqxLYTiBpihRrj5EGOSK1fAEC6pO1nIxS2LiS6kzgso5wPrXV6tYhNSGoKheIvuij7Roo+UfnzQBzq6G8K2+mrEftLnO88gBeT+uBTYYnRNrwFmUkEhSehr0jwvpck9vdalMQJZIhBAM8AHv8AzNJ/ZxHy2doZIF+VXLdccH9c0AYHiMTW0jWFyCl1aMvlkj76HofQ1jSWklhdWer2n31kK7T03dx+ua9A8c2UeueHrHXbbALW6xSsBkh14rhLe8WbT7/TblsbwJ4n/DB//XQBtazqzXuiOLYDyZU3so6wS+g9u9c5osgjMcsgVVlySO2c/Mvt607Q76ZLS4YASKE2TKRkjHRxU9vEk2mm4C/KxZZD/dI5Dj+tAGDrlisuryeVJ8s3zrjjccc/jWNa2v2qSONjs3qVjkHcg8f1rY1F2WWB1Y+bG/IJ7+3sRVK9cW8kotRmMv5qjoUbvj2oAoXEGX8iQ7ZYmKsB6etOt4N6OHAaRfldCeozwfrWwLiO6ulm8vMrjpjnPfP61m3ro1xHPauVTHKH9VP4UATrKZrGSLLJcWh3wtjll7qfXFMsZIlYRTNmGdcrKD91uvFRXE4Rw0jASRnckgHVSOh9RVOS6QYkGN54df4XHXPsaANae4+y3kd4Jt8xASRGPBA6MPqMVlXt20rSThs5YZXocetUpJ2dRGS2wHKjOSKiDlcYwcfj+FAEi5EvXk5IYUjeY5HOQDgZPf0pSGdt0akbecDnFMDsTgcEkUAOkkdn+fhlG3HTApY2ZMbDken9KfFG9zK0eMTAdD/EfT61HCCJgsg2noc0AWFaCaMI2I27cZwfekglESMfKRznnceDUMYUMQ5Kp2Yc4pyOoDbjnjlT0NAGnBqmFVTCFQ8Ha3bsf5VOlu7pLPAY9oAdlbqvvx/9eq6WtvIscsUkcwPBUnHXt9a3rKygMywXssEK7QBHOhU49mFAFGSKdFS5SGMpOMFY2GTx79KnsondTb7nheQj92zFTj6jvW1Dp+nQzbA7SOCGTdN1H+yRwR61t22lieT7TpUKQzBeUkkVv0/woAqXVpCLKK3ee8k8sZjlEYZo/bcDkD61WtYXt4Ulm8+6mlA8uSKfcV7c9xxW41nNch5DHaxzjh5ow0bIfUrzT4fCc0MDvbyxXLuMuWAZX+mDlfrQBmadYTvcRs8d5FcQtmOFlIVh1yWxzW4dQnnibzpIcOQgSddgHPJDZ5+tMa2vMun9n3iQRrmW2COwPuj54qpex21vbO0tjqJedC9u0rnBPo2en/1qAIr+0e3tPOtDeLbyMYwFfzC7f3vm7cVnrfT2144u7hItiBU+bAXp9efp0qzBd61Ppy2ttqAigUFlxMMqP9rd79MGpdO0qC3dLnXbg3MLkgW3noVUn+ImgCC58SeZaNBa3bXBR+Tk4/ofwrOnvJ55vOmkCvGMHzm+bb2AHb6CrniKSCCdX0i3WO3OM+WB5jn1B/rXNvsCiWW2ilYOdqeZ/F6saALGqXbTXSzgspKhFxhTj/Zxzz68VrWOvRQIkFwWdBHsjijQgc9ee5PqayYppGlEaLCpPIdSdufTPf8ADiqdxa3drMz3IkZbo7fOckBfp/hQB02nTma8b+zC8EgXBWO44jGOSzf4UviK/it0j23DXZOAsYB2E85bHfHqa4u+gltJ1t4ZsqP44ycE9eR3pwSZ5o43nuXkb5nkB5A/oKAOru9fgfS2QzyxlflSKJfve5P9BxXV3GrLLotlIyIJIYcwwE/MSRyVA7+56V5RAkD3e9JvJghJycg8/X1rROtXAV4IQxR49rXUrYYJ6AgfKDQB7F4S8QpHplrcGBIiU5aYkgc8nPX8a0fEy2usxzm8ufs9nHiR2I+aXjgH0B7L6Vw2m2a3LaOIb1J/LUO0O/bFGo53Eeg9T1q94tuZpmDWFsZ4EbckhfEatj74Xv7UAeceJtIHmXWpXBcB5AkMQ4J/DtgVh2Og6jfWNxfRWzC0ibYZSPlz6D1rroGbULhbK/dkton3XE6De5zyee2eme1dJ4y8U2V7p0Wg+GbNLXTo0AzGQQPfI6sfWgDxVV3yYByvrU0kSoowdzd+OntUs6LHPIIslVzg0ka5iOBk9j3oAt6VcSWtwiwudz4BA4Ar2aNE1jQ9PtLOVSifvbuRR0QdufU4FeMIXjgHlhhKSAT6ew+td/4S1mWDTxpkcZM843SPuwEX3PoP50Ad9p11cRW0/mNEGkby7aFF53Nx+QFelW1tBpttFZpGWESBc4HJxz+ua8m+HulXM3iJbjEsqgAWxlJ7n74Br2ua+htZDDEnmKnG8n7x7n880AeL+Er6M2uo6PdNmwvSXh3f8sZcDK/jjNeZXVv/AGfrS2zyfMGYI5PTk/LVqfUHsZpYHdwCyyAr6/3h/WqviPbczlwMSqol3jOM56/59aAI7KabT5pJolJkhY74mONy55H0PWphfkT3S2u77LJiYRnnAIwwH61k3E0spS4iUeYVO4ep7/596SCdBLFdQv5bbgHB6KfQ+xAxQBoa9Zz2NxbSZLW9wqtDMo4OOx+lZxY+ezxx7ghLAA/d9R9K0bvWVlszpky5hV/MhOM+U3cZ9D2rEttR+x3gd48wHKOvtQAXW+wn32khEZAlj78f/W6VXubo3FuzSbQ7HIYVFfOhKiIkxjlCeuCaolyAVHQnP40ATlxwjkkZ4GfumomGzIOCM4/GoyQcYHQY+tKWJPrQAo6gA/SpI4yzbcdR2qPb8qnPB96s21w8MyTbQzJ1B6MPQ0AFjN9nvEYjKA4ZW6Eehq3q9pFDcE2QZ4ZF3iM8lD3HvUmtWtrL5V5pbM1vMPmif70T+nuPes+3nmjkjYMQYzhcjofT6UAaU3nNpUF2YWLRnCXUYz+EnoR70W1q+qlpjcRR3ajOxgAH+lWdG8RTabeT+XDGbe6XZcwOAUf6enWsi/8AIE5ayWSKM5wjHJX8aALWo/YZkLQxtbXY4eM/dPuKyyDtzjAHFL80hYs2XPPPf8aI2cZ2kcc9KAJI41MG/wAxdwO0oeCavW13dWcY80StG42qrcqy+nNZ8M5QFSFZSejLmrazyeSLcPG8B5Vccp9M9KANS0e6uEf7KSgU7zbuRn6r3q3a6oBEnluXlTIZZDtJ9utZccF1ps0U1zbzCKTAWTGUPPqKk1nTiD9pDI8cndeSp9+/50AbWmeK9TsXw4mCoPuNJhgPQZ5qS08YTo4EZuPMlcnflfmB7H0rilDM6qWG7sW/QVt2FncW0kFzeQSR7ejNFuUj60Aeq6Z8Srqw01IUEzBV2uHYMTx646Vdi8S6je2G28jhubMruRFdQ8fHOfWvKb3WI592LZFuUUGNmTbn6Y69qyLjVbwzLJKwD9QNu0fj60AewzR2mp30UN3bNGSn7uKQr5Y9SBkHI9D9abe6foVhClo175M0OW82XDiX/ZB7V5PaahdXl95gl8q4PG/J6emKuvbXyzSPc3Z+zpyZFQuAx6Dn1oA9SvNP0/VrNCb3SbGcD5Ehfcw/M4zXOf8ACM2ltI0Nzd2kzn+FZPmx/IViaZavJC0kMW+XGDJKmxfqCaqrFcWtxiaWGLrhyfMGaAOrvlj0zY1lBBHIRgzFw7AfVuF/AVgeItRumgR7m7VAwZUJIkkP0HRR9Oay9VkHlu8YeQr1mcdT6gDtVTTrqzhjeR7eeaUDmWQ8Z7ACgCOyRntRNPcGNUOEiQfO59yegply8m2VzOyxuclEOBkdOa37FI9QhTEaWpP35ZQScZ6KvauX11oxqTrCWMMYAGR/SgCkzsECgFUJzgdPrip0u3eIW8ju0ZOW9TVaeUuTjOP1pIV3vkhiBye1AHZ+Edct7a+fzY2WNgAT1+Uf3vX6V2WvPdanEk8MnlW8w/0a36Myjq7gdF+vXNeZaPdRQTN9oHynAUAcDHr610r+K3hj8uIMzSjBfaN+B0HtQBf1O4RdGGnWzhf+W1zMidR6e+fSuUNxdHKWxCKxwD3x7VsQSz3FsI5iyLO4JCD5n9BVbV7KON3lTP2dMRBE4Jb2oAzNQsUikjRXXeyjp0A7knsKqW65uAigFB09h61Y2uzurxME7kDI47H1rfsfDsP9lyXtxPsZgThjjAFAHOElZPMXnn7uDjPt+VX9FnY6mklw5jjcrvx/dz0pIELP5cQZlI5yvOO2KftjtpBvUnC7ivoT0FAHumnM91px1eCV7OMMIrcRn5pPYD+7wf1ruNOuLs2URFpuGOCzgE89a8w+H9jqmreG7a6W5sVPzxW6XEoRiAfm2pjJJIxk4r1DStIvY9Ot1lf5wvzbuuaAPl++keW6ZCMybd0fvj/JptjOonjil5iIK56kZH6ioTIwm+zzhA8THa/4evpVJt0kks0OAY2zgdOe3/16AHzO9rczpKhwXDKw5/Ee3rVS9kLjzIwuJl2uB/Fj+tOuNS81Y5CuSMEg5/zileQKhkgUPBIpYr3Rh1oAz7GdorhHJ3LjaVPcelWtSfy3zGN9vMNyk9c45FU7iNWJkhwUPI9VPcVGXZ4OD0OQD/OgBFcKhR8sp7g8rUcrBuR94HnjrSM+W3LwfQ004xyCD1FADevvThgrntRt44xj69KCCMg8etAD2QqmQcow4NIueucU+DGGUjgjJxyR71qQ6RdtbPcW6CaNPvFeePX6UAZrPIIVK8ISGyvY/wBDRJMZZA7oNx4Yj+L60ioWB8pgV/iGef8A69K0ZjALAFGPDCgBsiqp+TOPf0pQ2B0PPXNSQw73RUGSegNdVbeDr1bKK+cI1s+QG6qD2zjkUAccRnJGcfWlHGQQGB/SutOiWxRJ3m8uLGyVF5aM+vvXV6l4IsJdAM0MgluAAVeMBGcfQ96APJvl7n9KlS4eMrtIG056cU66ga3uGhBOR6jGK19L8P3GpqHiYZGCVYgZHs3SgBbSS+1K3eK0LoFG5kib5WPUfL2Ndx4fXTtZ0VNN16+isJgSi+dEPyBH9aqaDZf2HJvWVVYjEkT4DJ+Hf8M1o6sP7TZZLgJPBuGJEiUbRj+I5z+YoAx5/DejaLqCw/2pZ6gpGASxQg+5xipfEujXcdqJIJbYWOP3ix3BwR/LNdHbNc6XYBdGsrK7jPDfa1jYD1w6nn8axJYLjV3JgsrOAD5nWOYIG47DpQBw2obJFBit7k7BgOz7gPy61V3odovFyo52x9T9a7bVdGhkti50y+SQAgEShkJ9eOK5yHw5qU92AtsybjkBXXgfU0Aa2na7a2umKIS8Eg4JW1GTzwN1XbnxGfsEa38zRsrBokjUEk++KIPB2qgKJrdlt1OfOeZTz14Fc14lkNrObVJ1nUY+dlG79KALtx4ll1C4jXWJDcRKRkSgjGDxhBxXSaRaaJNci7vDeJA2E2wphCMd2xwK8wJw+5icVur4nvIrL7NasYkxj3oA9K8T6p4cuNKOmaZHLLLt24ijK46Yy7c/lXCCGCF4Yr1hDg8neCUHcYHeudiurkTNIJWG7kknmq80kk74d2f6igDq/EupaT5EVrozSOUPLuMZ4rlpNzHaVCkHkk5JqEgDgFiT6VYS2KsBMdhIyF6k0ARhcfdHHqe9ODAADOD3NTssZDLCjNIe5HT2pZrKaFN0xRDjO0sM0ARQyeXjYFHqepp252y/BwepPFSCzkaLzdpWMjgsMF/oKc8DRRBpSV7KPegDR0+eS7mAEot7aNfncHk+vNXhaxXa/wChqcyMEj3N+vtXMnCqd2STzt5/WrthqMkDhsgEYAyPlUev1oA2ryKWzYC3ZGSIcDqN3TOKrRzzSR7b4vkfMqE8E+9FndvcXC/J5cKglS5POf4if5Ukj/6S7M7eX/E5GTweiigDY0xA1vcNFgKF3SuOuP6elVNQjRETI/eO27YpzsX396uaa/2q3WO2YAdUUDgf7bHuauaHptnNeP8AaZ90EP7yaQ9ZG7KKAPTPglYaRZ6QupXbmPV5C5n3ISFi3YVYz0GeCTyfpXpeoXiSXkjNciMnHyZ6DAxXmy3qFLRbSJVmlbKIB0xxn6D+ddMJrdPlkiMrj7z4zk0AfNesyr9sMkYIyQsi4+ZTjhvpVKGZ45DhVDOu0g8q/pT75muXlAG25iC59WFZ8N4ssRtrhSowQrZ5UigC3aeWUlSRO7BkYcr6jH61VeMIrpDKSOSP/wBdS3dwzDePluE+V2H/AC1GOGHvWQZXDlgTnPOaAJ45GUSIRjI5461U+YDuBmpR+8AblT69s05onCNvT33ds0AQBcnHTnrUsMMk5KRqWbtUYHOcHHtz9a1tFtpPtCzAeYnQ7eTigCC106Y3caSARlj8pb19DXXt4T+2WiBE2z7coAOWHdR6nuPUVsT6ZDe6ZG0iiOUgFJlx83HAb0P+FUtN1u6sd1jcpvkiG6FxxnHIIFAHMr4eeSUxWUub1RxERguPb39q3/Cc1zYzq8YWOYfLJDIMK/Ygjsab4gvItdEep2kcltqMTDzMdW9eP61taLeWmt24j1rYl5jbFqEeMeyvj+tAGV4h8LxX7G7sbV7OQgl4xjk+oA/pXPR6Dd28++SF54F5KqPvL7V1l14gNmZtPvFeVoztDIcOox1X1Fc/JrWbj/R7h1ZuckcFvcdqANnRNO0UQpPaSpKW6K+A8bf3Tnr6Vp3t1cRCWaxf7OrYSeNeY299v8J9xXCNqMr3jyXEQWRj8wYbRJitGS+iQCWOee3MgCSQOAxHPvyRQBPHcMttKbmKKWJztZlGCnoc/wBK6XwjrOoachRIYtQR84s7ptyTr/ejY/yrl9CsX+1S7SjIQSwUnY4PY56fWuo03T7WTFvaGQQFtzWk5+63qrjkdOtAFm+1XQRKLtdJjiU5D2LxhtrDrsb09qx7/XbOMmTRrZ7VTy2EBAPuo/Kn67o9yZna3ubtbpckQXCBi4/2W6N/OqFw+kT6YzahZy2l+gx5yEgSEeo7GgDA1DU47udy6vHKTyYQQpP+7XffDuytrsZnu3gI5J3ENj3Brz+H7B5xW8tJAuflcOVDD6+tW47W2d1Om3E9qpGP30o25/3h/wDWoA9k1u68E2imG8nMMrD/AF1s+M/7wAxn61wt54l0jR7cw6SBexn7sjg5I9D61xGp6deWc5af9+GPLpKG3D2INZrSOkboN6IRnBoA29T8TTy/Ja3ksMec+VHIVUH0x/Sse4vp5sGSR2Yd95Br2Twe2oyeCb6DV9Lt2dNMk+xWv9hqpuIvLysxu8EAgZODySK8cNqEiVpVuEB/i2gqfxoAcNSuljEfnzFenzMSB9KqP+9y4dnc9d1Wm0+Zx+5idxjlv/1VEYlWLDgJKO20kigCFwI1wVTeeueTUcURlOQyg/3c9antYJLp2CRB2A6kGpbaO2hmcXql9p6RkAH8aAKzLsBRjGCDzzzTQWQZVgc9xU92hmk8y3tDHD0AHP5mmQ2dw7BhHgdBnigCON3L8MExznFWYZ3ikLybuerHk49qsXlktnEhmV/NJx93H061UihkeNpGhlKD+NlO0f0oAupc20MJeAs9wei8/rTRc7VUlQ13u6EdPbmq1vIyA+QwD92CioVlkDMfvknliPzoA6m0eadSSYSw4yTlY/8AE1Q1K3McjSvOZnz06/p7Vl2lysEx81TID2DYAPr71fkvUkfDLsTom0cD/H60AZwDFsnJJ55PJ+tWrW0e4iMnOM/h+dQGNzKMIxLdFxk/jVtZXRlh9MYROB+dAFqwj2IDJ8ozgbjgflUbSETl3beegjB+79aluoCYCBgtjnB6VZW1MFoGkjEjkDCAcAerUAaWmwCWEpAX2n5nZF5c+gH6V2D6Fv0yBjH9nu1AYqW4hX/a/wBqsPwozadayXFwfLuZQDGzL80a+qr2+prqbDUQY4X8iV/NJWCBiSXOfvsfT+dADrK+mt7iFVBGR5fmvw+O+B6nsK6tJLmRQ0cbBD0ANUNI0yyt5vtc8ZnunbbGBy0jn+6vYf7Vdna6TJHbor3SxsBykUeVX2BoA+Yp3Tdb3aDDL8jg9az9R01UuFngP+j3B4OD+7f0NPuiBqbIUZYZB86+jYq7PDLYRNbXib4ZlDDBxvXHDA+tAGHHKctbXS5GcKx/gNQywjKswBI4Y/yNTSuBKgf5ht27v7654/EUKGBaLcVljBKN2cehoArKojLxsQVI4OMEVLZTNnyGZfLJyFfgH8e1X7OCC9XYyskp4OOx7fhUdlpzyy/ZZMR3JP7pnPyuf7ufegBdOslkZ/LT5wN3lt0YVoQQtpV1Hc2gSa0mbBjbsccofQ+hqSwVLOTe4eNkJ3qRl0PqB3HqPSp9Xke3neaBFeKdQ00Q+5J6Mh9f5UAdPYzWmoaeEWTbbS/Kd/Dwt6Nz096zrnRmt777PqRYlW3QSdDj/ZbuK5ZNSCSpcW3zIRhs9cd1cf1roP8AhJCbAWF7G0tk2Gh3fehbHBU9+f8ACgB2sLFaKHaRcsfluIxhgf8AaHb6965174xyMqhY7g5VyuPLlXrkgd/cVDq93JPHhH3R4+bI5x61UsbMyqNxJUE4CnkH1FAE1950s8dxJI6YwEn2khfYmgBpl4eOG7Q5w33ZPcVesoJFlMElwyGQYGRw/s3vxWhLplpaWYcsrtFklHGQaAK9tdxSwrFqNuJQuPkOFce6nowqbU4LSO1geJJWTH3HGeM9j/TtUJeGa0CWVu0kRw7wSc7T6xntTtMEy258vMlpyDGzfvIz/WgC/p2sGyt1nhZWaM4KkZdRjuO4qe48X6fckXMFmYLv+MxjCv8Ah09agtNAN8hvdPKzQZw4f5WH17V1tp4Z0iOyV76zvLZ+v2iBgyfjgfzH40AcumtLemW4ghuHOdxUu2VOOox0/CooZtSu5ZBEruJuNs4yCe3J713un3MWnmPZbW7WZ/5elblPfHUfhkVrtcWr3AimeCQXOcENuik9nIHyk+tAHAWXgq/mgI1LTL2FG/jRwqNn0PSsm88NPp2obLI3ZkPJgmhBYj2I4avoLw/BYaJCsouNZs7Z/wCGF1nt0+ncCmeKfBVp4vhSbTdZQkcqyYBz+HegD50v7a5hO2/0u1iJI/eeW0e78OhqhJ5SlooYJAcH/Vgsp9sGun+IPhLxXoBCalPLd2q4KSJuYfy4rhXvbpnx58gPp0FAHcaNd+IbzRl0G11K9h0+crEbUuwhIZgOVAJC5OTWPq+gahpU9xZ6g8cUcDtGZAzbHI4O3IGRWRo+u6jpGoRXtjdzpMjK5CyMokAIO1tpGVPcVa8Ya5qWt6tNJqt8t3tkZo/KlaSGMNziPJ4H+FAGbCkS3IQSPLFnHykqDWzf2Ugs4kUbYGxlgSAPqTXORyNEwdG2kHjjPNSXOoXM8eyWdmT+72oA37jSLGCyIiv1WZwCEMhP8qSPw9JDYJPeTW3lOcKASPxJrmFcKwZAUYfxcmtRL62k2teyXE7KMAE4H5CgDcGmQQBYrW6S6kU5dIlOxfqx71Wuo7nCSxyi1CAgfJjP0B7+9WNN8ZyaZaGHTLOBGPG9wST+JrA1fW7/AFSYy30/mvzzjt6fSgCzZ7vtvnSLJfT5ztzn8TWvNJqGtlo78xrbQDPlA7B7cDFZOj+JLjTzhUiKdSdvNWZPEkF3OWvbQeTndsj+85927UASpozT2zzXUlvZWyHCxqcu59ABz+JNZ8ttE6tHaQTTTZ5bqAPYDirBvRq10Ps1nHGANqoG2oo9Se5rfeOKy09ori5E0jDAtLIYDN/tt/hQBx1xAtrmPAafvzkJVRGKk9T9B0rTWyluLhxOEiiQ5ZIyDt+ppitGcLBETEvVhzxQBUScoXIZhkc8c/nVmN/JPnsjF24UAYA96hdGaclItu3sOfzp3mOwDSPux0Qf1NAGhbi4MBmcrDHjPzdfr/8AWqzFqckZVVII6sCvXHc+1ZkDK86NJ5ksxIxz8o9K14LYIkkzpkjgyP8AdX2HqaAN3TJ7rUxveR0tchpXKjdLjoM9hXR2+pXbX/k25ihicbR8ufLT/PrXDxSzRMZLhpBEBujjVvmY/wBBWvYXP2eOOS6hQSH/AFUYOATn7z9yM/nQB7J4UhitYn1KcyfZeY45mJMsx7hfTPr6dK6ZNck2jyWWGMcCONAVX2z3ryXTtdi1HfPdzvBbQgRvI3AP+yi+teiWYu2tYjb26QxFRsSWTa4HuO3rQB88abBa6hrUaXCui7wuO6k84rqNX0pvs8ukTIjTqnm2hLcOuen6VS0S0ji1sGWJ5bKYBJQo+aI9mU+3+Neg6vpTahp0du8q/wBq2g8y0nCgC4T19icEEUAeE6vbxwyo33SSVdG/gYUl9AHjilQruHU54IIrt/FdjbapYsWVbfUIMh0KAFm7g+/HWvOY5JrZdpJeEEZGegNAFo200UYltdwIwWQtyP8A61auiapZtK9rrMQWGQY8zPKEev8AjWbb+dJbyLHglQcL1BXPY/jUOI7tdj/JOv3W/vD0PvQB3eoxRzwDdKkqxYT7TnlM9FkA5IPGGrkroTWsjWuQAfmVWOdp9j0wfUda0/D2poFNvd4iuCMJOOki+jVnanL9lk2TRM9uSdhzny+e3t7UAYkiypcO4BjlBzjPerNrqEoQx7RgDOxunuR/hS/NLMWh/eK3Reo6dPan2tmlzG/kufNC8xOORQBFCYpbpkmbymbIV/4SfQ1LbQpG7xXZeBwf9aOV/H/GpI9EujuIG5Oxxlc+/p9aZa226Ty7lWDEDaxP6GgC/DPdmyazm2XMTZ8mbqQfT3qtewzIiSw3PnhTh+NrJ7MPSrtqU05XURh+Tuhc4PTse9Q3588CaBMrIBlVHzfT3oApLftDADbvtYH5o26g+qn0qCfUJ55PMLbJehkQkE/WoXiXJCyZx2bgj2pyWN05UJE/OMHsfxoA7LwBqlxYXASRl+dTweCRnt2I9q76I6nOJX0qS3SdTlTHJt3D0KGvLdJuri3xBdQBxjqj7XX8+DXS6te3V1ArxPGz8ASBPKckfpn6GgDP8QtezXVx9ug8qUDE6RnKk55O0cg1n2GjW/kefa6iNucvGTsdP8fwqYTXRmBmkm8wZCOcNn2Oea018S3MH7iextnwMGRowcfUYoAfp2hxT2+U8RS25bBVZHOxj9RxityG11WC2kb7fpaEHGWIG4fVeawrqaDVIcNZpbyKMrLbuPKfHTK9jUFrCIZUeawlQjHKNhWH0NAGrFrNq8jW+t6l9lLcF7Vmct+O4j9Kdr3hXRr+xN1o11c3Eo6tNwD+NZ+v/ZlRd1jKpPd3XaaZ4Lv9RtvEFtbadbC5eWQbbRY/NEuOSNvfgEke1AHD3Vo9vJtY7iOu0dKbPHAkFu0E8jzOpM0bRbREc8ANn5uO/HWvfPiNoFxeapeN/ZCoXZijbTHuX1AA5rx/WNFEAWNIil1vLO7uVG3jC7SOoOec8+goA5wKXO0YGPU4pssbxsQ+P+AmnzRmJyrcY9DmoSOeMYoAbtwCT0/lSdqcevqKaQOe4oAXtjnilOMDGfc0mRjJ6UqjdhVBYk4GOSaAG8gcZo9MVLbW811OkFtDJNM+dscYyzcZOAPbNLb28ly5WEKW2lzucLwOvJIH4UARJJIp+V3A7hTitrT5JWtihnKF+NsYy59s9qzYYImWRprmOHEZZQyli7cfLx0PueOK674a22h3F5djWbq5im+zTeXGIVKY28MGLg7x2GPxoApmJUSO3v7lYbcgYgj++/sxqHWLtURLayKooyBEi/dGO57mtCW30i1nf7JLLLAOVaVAJ5PqASF/M1lXMkk07La2vkx5yztwce9AGbIWgBUlgWHOetXbOOMwq1wdq/3R1P1oitw10WzhR9536GtPSNBfUZhFZq8hc8ZHb2oAhsvLLh1jbyV/vDG76+1dVptrJfzwS3iM/ljdFAoxFGv99/8ACq8+gmwmS3+0fa7/AB/qYl3CL6+pr0/w14ebTtGFxqBS3O3dsbBJbHU+p5oA871uxnmied4vs9lGRtkC4aU+w9KoXIihWKfyVxGpwznLyH1PtW34wulkgbEzM7SHI3cqB6isix0Y3CDzJZJ55MFYcZ2qf4mPYUAWtCmhtIk1Ge4ja93ZjRxuVcnqB3P8qs3eqXl3cyTyXQLueSWIrO1CwhsjhZGeVVxgYwg9vei0uzFboga2QD+FlDHr3JoA7nwpEkVxEbq3b7FdHCTd4mx91v8AZPY10uoWskKi0Mi7lO+2uOynP3SfX19aq/Bt4NY0N7GabzJVYkZ4K9MEV1Ou6LdC3c2203EH+utzn96o/iX3oA8f8cpDdO10oW31KEFLmLOPNHZsdx715U+1JJI2G3LHaWPX1U16b45miF5FHfR7gMtHJzlcduPryK4jWdOheMz27pIvcd+nH1oAz1t7izthdWrmS3JKkL1QkUKBdxiYPtljI3MDyR60zTZ5bUOYnXyyMMrdD9fSl8gs4aIiCc8q3VZB3FAFy5V4donBTeMq2OH56g+vFV83E0rrhX5+6T97/A1e0TVhFE9nqluLqxyS8B+8h/vIeox6U6606GA/btCu1ubVsFoW/wBZH6cdxQBkIxgkZot8E4GWRxw+O31q19rhuY8urWtx0Dg/Kxx69q1rO7tbyEx3a7WCFBIeqHP+eDV2GytS3lzqsPmYxIq7opewyOxoA5m11G8t7z5piki9mO3d7Z7VoRXUty3nII3IyHikUBvoex+vtRrFkLabbc2wkiA4mgbdj8euPY1UspUMoVC25iQHUZ/MUAW7+eG6VkjkaCTgGKfqv0PpRpIOTGsjCRQMq3zK3r7j61aurRflN2u04BWTG5f/ANVU/JMTjKgKM7JFyR9R3AoA37awt7qc+esQlP3re4IBb/cfv9DU02l21pIk9jdS2kZxuhmQkDHr/d+vSqtiZryDZdpFcKoGG2gnn0x/Kq9xeGNjbrLIoXICE5wPQE/yNAHW3OmadqWnK7GB5FHEigLIPqRwRWF4e0+e6ka3guxDKo5jlkykg/l2rMsr6WN2iCOVyDkx5Xn+VX7O6eCRvO0794MlZUJG09uvGKAJ/EPhq7t5EP2Mxb2+YpKGjxntj+VH/COXaWhlgtba4YLxLFN8wHuuean/AOErknja1nSAITtKzEY/z7isEndqDyxym3C8qsL7149MnNAGvpmrWtvcPa6raQiUHGZYv64zU1+8kdwk0F1BBAMYSMOoOPYjFH9vx/ZRb3+lx3wUcSTxjP6HNQ2t7ASSjW0FsR/x7yq5X8DmgBL7WYbgBLmOTK5+YnzF+o7+9ReHJ4E1i3km1EW1mhLvcWwJuEGDwmMEM33c9s1MEhkkb7LHZQFSMOCT+VVdL1e58OeJbHV5V0zUBZuZFif5QTggZIGQQeR70Aeuw+HnvhDOmo6+JfJWR7DUroSXKIx+UkJkqCBnBGa89+IfheHT7SaSG5tT50gLPI/mShh2BzkDnkY9Kr33jx9QluxoWhW+lSX7A31xBPLM9w24spLMflPJ+uaq29xMlxuktZjczI8Qa2YF3Vh8y9Ocj+VAHA3lpJbxQzO8TrNu2hZAXGDj5l6rntnrVWcRqIzFI7uy7nBTaFbJ4BzyMY5461r6wdK3sLOCdJc87+PzzWKw64+lADrnyS6fZvNwUG4ygff74x29O9Fy0LzFraJ4o8D5XfecgDJzgdTzjtnHNRkc84FBHqKAJZbgNeGeCFLbL70jjJKx+mNxJ/PNIbmf7X9pEzpc7/M8xDtYN1yCOh+lQkdM0o5NACkkkkkktySetGc8HkdaTFKV4HrQAfxZ/nWhpFm17cbd2FBBYkdKr2drcXc6w28byO3QKpP6V20egz6Rpxe5thGx5xIw3E/SgDNv5ILNFisVRm/iKDk+xNVcSSnMp8uLrgDJY+gH9amuLW52FpHjhU9B3b8O1QWkd1Fdo8L75QeCwzt98UAalhoZuXjlus29lnq6nGfT3PtXXTa5aaNZNa6JZvDKy/PeSj96R3Ciqlobq5VXuriRPLX5ricgBf8AdX1qE6hZzBobUEQgfPNIPnkP17D0AoA1/h+82o6uiRJHbQb/AJ3cZOcdf9o+54r1PxTKLbS/J0238+fbh55HwEHrnt9BXnHwy0a9u71riBDKxfahYFUQe9eo+K1j0Dw3JNqUi3EqocIo2q7emPTNAHg93aSQLJI0cBklJYyFsrFzknnqaF1OOztNkVykcsh+eRMmRv8AaY9vpU9zp2oa00moauWhswC0VvGvb/D3qnY6VDCBqF5PDbwqcxIy7sfh/EfegC/4f8Ialq8NxqEAVLW3Qtvu5SvnMOSB3JA/CsVtu4lzGWPXaMCu28JeNlDiyurCzmsre2lRLu4jZpCW5Ctg4wT1x6CvPpBarIwaSfIJ+4ML+GTQB6t4F09be4iv9Pla2mRcMeoH1H909/Svbo0XXLZHybXVbcYDcEH/AOKU15P4ZsRHF5ljIqzxDKFydrKRwD7V6n4fm+1RRq6eXdJjyznjP936elAHjXxY8Pm6eUtGYL2LJeJSNj+6+oPavE1t3tJWliJkhc4ZG6jjkGvsTx1psesaZKjlkuYQVLAfMjehHpXy94p0q60zUJ3UI6n5ioP3x/eHvQBzEMUUvFszxyAfdI5HsR3FS2jxxZtp49quxZSOFB9vQ0PcR3IDupV4m5OMFc/0qxd20d7bAxH/AEgYO1mwGXFAEcyJHudgsqk9QNpH19G9+hqla3EdtdPndND1Yj5ZF9x+PalijkAKzb2VV+bHLKO3H8Qp8oW2dJcAknsflYY6+x9RQBctWtJr1Dcv/rD+7mQfez/eHrWvDbtYztHBcRz2sozsY8Yzztrm7hYZB/ozbJJBuEbDg8djUcMrMY4cSRTAY3BsjjuKAO0utPtZLcmeObyVz+8g+8v1XPNZE2i26fvROtzAcYkj+WVRxzjviktptSspUuHUlSeZEP3gfbsavvqtjIpadJEV+N9um4ZB7qeRQBVMt1aRpEZ0uLdwcFuGHse34HrVVLhmbybi18606uIhtkiHqB/+v0qxJdwxbnWWC6tuc5UkYI6EdRUpjgKDzYJo4SQ0U8BBZDjrjuPpzQBrW3hcNaJf6FqAuIyu5opflf8ATjNc7q81sLjPmFJVP3XXkeoxWjpupwwXTLLO0LN8oubccOPV0NP1XR7macyiSOZWIZXjIyOP7p5oAg0e3tNQVTbXyx3OMeTK2zP0PQ0wXVxa6gY4pZIZkJBjJO09uD0pLKG9gkAS0hugOo6H8uo/GtWeG11JdgAtpw3Mbtt/JuRQBh3l9i4DT2UJbcCRPF6+hBGamvlR0hYwomemAcEeqsM1POl9py7CjzQHG4hlfArbtdOt5rLKzwTRv8zQ3CGIjjsw/nQBj6Za3UzmbTY7YYAyHkBJ/A0sk08Nybe5tkgZs/LAwAYH/ZINW47vSbLdD9mW3uOgZn81D+IFEuo6XcgRyxWDTBjykcq8diD/AI0AH/COWd6oljilMoI4SdVb/vnFc7qtrLp+6OSElRkHz8cflXR23hObWxv02K6VscMD8v4Gui0vwq9ltTWpbtF3cqSjhh+PXmgDO+H+qab/AGFq+n3GnWayXXkYKyTBbjaWOZCGwuM8bcd6reIp7LT40Rrez1EDfuh82UEg4wMg8Y9ep712dzp/h+C3drT7akyjj9yyc/hxXCa1bu4d3Z2wTtKLjP1zQBR+LWtabrPiG5k023tnwyH7bFPI5mGwDG08ADpkelcEwyOMVpamsa3K7J5Z8opfdHs2NjlffB796zmJDfLmgBnfnAFIAM+tKxO7LDP1pQpOeKAE2nOQMd+tJg8Z4pSPmCgHJ4x/StrTfDupakm+1s5SnHzthV69iaAMQ5xzjNami6Lf6q5SzhYqvLPg4H5V0Fj4JuYB5+rpJHAp/hZVB+hPWtt9fkSxNnotssEAHzSFyT7+goAgs5H0S1eC2W4jkA+YoBHk/hyfzFZTzT3szv5bqq48yedx8v8Au+lJbz3TP9ks7dcucs5fkn6muq03wtYQIkmu30ayt923jOfzP+FAHH+ZE8vlWKLPITyxy5J9c11/h3wvetatcX00dtEBuEduAGX3LHgfhWi0NhaThNKtxKV53PtREHsf68mjVrybUYBbSXlvFZgcxwd+2Mck/jQBzE1nJfXbW1r80C8nY5ZmA77jzj34FbegaFdy3EcMdsgMhKgxjMgUjGATwD71Z8P+FNSkUssptNNxndIoDynsMdcda9k8IaPqkEEe2yhQlTmUt85GOgPYfrQB0HhfSY/D+hhWRFKICVQ8Ae5PU+5rzTxfNe6pdyX00INvCT5HmnbH/vEdWr1fxD5dppTSahOIkA6IMgn6dzXzf8Q9cN3I8ImkS2YlSqZZ2HuegHtQBk6v4kjjjkaS4N3MDn5RtiX6Act9Olck8s+pXTT3UrKCN0ceQpx3J9PpSXJiWRMWxCEfukAOW929KrRzK0jP8jSZ+ZiMJGPQepoAuRrP5xiglLE9FzgD3NWV8hFCvNIzDqypkH9aoRy2qSh5ZWcA8KB94++KcxldixdIsk/JgnFAHt0Hm2Kw3FjI0gGDEwbG/I5jYdm/nXp3hDUba+toJlwqSdGX+Fscgj9K8r0q5tLq2C2kqGGTG126IR/yzkH8m6itbwre3ukagzQxtJZs372Fj/F3+je/RvrQB7VqNitzBvB2ToMBh0b2YdxXzt8SbeKS7uoJLV7S8jY4Rl+STI6o3avovRbyG+sFlt2yhABRjyh/ukdq5bxxo8F86J5KvMoLoSmcjuPcUAfIMek3F1cSKkchkHLYHzD8KqXlje6UpW6VxH1HYj0Ir6bsPCduJTcWVqpST5ZIAvzfh71X1DwjDqUclhqOn+fCOYbnbhlH9xh1/GgD5ztre61QR/Y0/ejIYDqw9akubGS0Vre+haLf0OOGr1JfAN5omquLGM+VJ80M2DgHup9T+tWbvSl1K1e21PT9l/H0cfKR7+470AeMpYPEhPmqY84UsOB/hVm+sbiKKGea1cwMcrIhGDgdQ3evWD4KuZ7Zmh0/EsXX5MiRfXjhh/Kq2seD7/TrKK4sLKRrSYhZYkQyW5/Dqh96APPLHWTaoB5nnRqAW3D5gPQjvSpBDqV2ZtIkjNywO63YgBvzrdufA9+0r3FnAhIGfsr5JI/2TjmsyTQ5IyXSCS2dT2XlPX3H40AZkunCaQ/IbO8Q5a2k7+4bv+Na3h8LAdjvgA8gEdfofxqO51u73C11WKG5+X5HlUhsf735UR6daXgeS3uRbTYJEco3K3GeD1H40AdZL4X0jWQjSSPZT85lhAw2fVT1qve+EdY0qzzp15DqttgfKwCOv0yf5HNZenWOoxws0EEnOCwhPmIf+Ant7V3Hhxrea2Md4slnLjaRIS8D++DytAHJeGrm7aXK2sU10mR5bv5bj2yf5V1U99a3iLBrnhy4hlGAJgAHX3DgYNc54j0aTTL7z7LCqxyu1t8bHvgjpz61SsfF9/DJ9nuJ5IkxyJclaAOk1PwtEkHmWN/dNFjgSWwdkyc9jz19K2vDvh7z7EKbu1uVwMGM7HwPVT3rjJNWFw4f94xznFvOQrezLzXRaJrujz222Cx2XaDBjDYbPtnk0AV9V+GTXlwZrSaaRCSfkVcr+Heqtv4FvbVmRRaXXIJjmVQw/Otu38dX+nXjwy2d1boDxJgMCM9x1/WpNb8eG4gUS6Vb3oz99lZWGe/rQBhTyXPhtNwsooTkkARsP1V6y/8AhLdU1WUiO1QnOM72P5biaZd6pa3tyDdG4+y/8+/LEfQsa6PS9I8JakgWfVbvTWPVZbZVP4N0oA5q+nd4f9Ntb7eFzlZBt98DFclqZ8qQlJ5UizjYx5P5V7fF4G8FwQsy+KJJQRnkI2P1rh9c8LeFJ7rydP1y6kmJ4LRoifTOcUAYGofD7Ul8KW+sRRs1x5kguIWu4XURqoYSK2/uDjZyeM98VwpUuMoMj8q7vUvDd7b6NFYy3yPpkUrTxwpskAdhgtkc8gCsm1062gct5gdl6gKc/TmgDm4LeWaQJDE0rnoqjNdLp3hDVriLfdWv2aHGfMnlCAD6d60FurKJ1iaC4RuzK6j8eBVu5gmntzIsskoxwLi4yB9F/wA9KAJ7Hw7p2mqki2zatdEg5jYiNfxrfm8X22j2RhWGCK6CkBIo2ZkP1PSuQbVtUhTyRsWIcYE2fyAqjPLNIxM0sUKejEAfl3oAtXV7eatcGedpNzHgzy8/gM8Vr6L4H13Vzkh4bf8A56MM8D0X/GsbS9YOmz+ZaQw3bDkfu+Pzrqm8Z+ILqA+fJ9lh7JF8pP8AWgC1d6TpPhqFh5qy3ajc25sufwHQcVxd/ffaJZJfs7KCceYG+b8Cadc3087O8UBO48sx6mm6fa3F7cDzJILSHqzvycf0NADtCUXN3Gbm0lZCeVeXivStDvNHtp8RW0MsyAEgbQqViWGmQXRjsrGWXp+9nRCzP6jivTfC3w6sCYi1n8q4dUcfMx9fb6mgDR8O2Mmo3Edy8AHp827Ar0R3ksbQiC3LFRncx2jP86dbww6RYExpbQhF6joP6mvOvEOtT3itJc6pJb6epz5jHbv9kQfz5NAGR4r1qS51HyJ45L2bHOHxFDz3ArzPxVe2y3Cq+2aZM/uI8AZ9WP8AStrW2v8AUYni06M6TYHpJK2JpTnrjqO/WuB1i0/s+Qw28u+VhlwmS59yTQBh6jK8tw8lxlELcjPQen/1qyphG07bWbYPuoBjA9T6VbvidxVsNJyCzN09hVSJnt4tsRDM/TaMn8KAJyJI138RjorEZP4D+tQCa4bkByPzqWB8sUkXdID/ABPke1Wi0qkgOqj0xmgDp/Mex1MS2f7iQgHC/wCrlHXA7fgeler+GLuPU7eOW2ZUvUUI8T9JRgfLiuAtXhltTcRRCe0zi4tmHTjqPQ1eiP8AY8aXts8k2lgA9D5tvn/0Jf1FAHs2i6x9nuf3LCC6AG6NzwwHY+o9+ozXY2Ot2upo6oPLu4CGMMhBPTqp7g+o/GvD08T2l1HFbaxK2yT5ra+jAyh9yO4qnd+IL2wvYLe9lUTZzaXaECO4HbnHyt+h70AfQcclpfRGe2ZIph6nBBB6EVVXV7BrkRXrLa3S/KJHxg+2a8YPii5TNxHK0dySFkVhjJ6YYf1FRf2692vmXkSvC58uVGG+NvY91PoaAPfsWk5aB1gff8zRtyj+4561j6x4etp41lt4kaaDlQ4+eP8A3T6Y7GvNUvh9jUWc5ntFA2q74liYdMH+Ie9UYfH9zpF+Ybm5nKg/dnQEKPZvT2NAHp2ialaW0zQiMxTpnzLckDd7xn19jWml1p968v8AZN7Bb3+MywyDAcf3ZEPbPcV5xLqem+KjGIZfs2ouu5WkGFbPQqeh6dK0/DtreRaiqaidt7Hyk+0NkcevOPzoA6QWtpNO0WoaXGjhcvEh3Lj+8h7j9RWJ40+H1rqduLrSpEjl2gBn3FSPQsOR+orrtRmdLRDqELYjPyXFucpn3HUVgz+MIVDtDceTPxl9u5T/ALw6/jQB86a/od1oEi22pWiNHgkCQbk/4C3b8OPasXGmTShJrdraQPwC2cg+hzX0Hquo6T4ktrm01SABgMN5Jxj/AGgO49xXlmueETBKf7KS21G0HJ2vsmT0DA9eKAK3hhP7NZ5NPY3MLYZow+WGP9nr+Wa6uTUo72BmslilkH3oXPzfTnmuLtLTSoZ1jv4rvT588+YvyH3B/wAM1o6i1jHBHHcTpcIMbJC24j23dR+NAHP6m7LfkRWq2R4JjbIjJ7/KePyxWbd7FukabSpihB3GGQun1HP6VFqN0r3DRx3EsiAfcLlwPxPNWrRLOZNsd5JBKOQssWRnHqOaAK1++lIu5IGglGDmRGjI+pHFV7dVuo1adt6oODHMCR+dbSXd9cK2neVFe9ANoIJX8etQN4fvrZmZ7GaPOflZOD/MCgCa1tba7VYotXRdp/1dwpyKkvrX7LbFJLpZ4wMYiOR/jWRFaOlwpiskV9wDLJwP04r1n4eeFLe+aOS+0CxueOHE7gnn0BxQB46LmS3JVJzs3ZAdMkcd81YikvbhV8uUeWOwjP8AQV9h2XgXQmtwtx4dtI2HOFfd+OTisnXfht4ZMLvDpZtXwclSSPxwaAPmiS4lhjKGPzG5HGDn8DWYdYvdNYbVgEBOSrW4Oa9C8X+G9L0l3eHz/OJ4aKQnBz1IY1h6ffOmBdyNcxDt5Kcf8C9aAEsPFeozW3l2UWnxtj72FGePSuO1GS9m1B5L6RLlzwCgwV9hxivYNM1jSIozHZwrDOe77GGe/SpdT1u3W3YH7LNKOpBA5+mKAPNrCytbiNS0N2GfjMaA/riuhg+H9tPF5jKCzc/6S54+oApg8ZXFvMyHVb1EAwIoQqBefUrVWXxZNcT7l1S5xnG1pvMP/oOB+NADLzTbXQpiLiCF0/u2UBZs/wC89Zep3kF6GjsdFvZH/vSKF/lWqus317uUXTIpON0lwAfyA/nWnpVxDG3l3Nw1xL12RlpG/pigDz77MkUq5hMMo/gyWP4AVozWt68Kfu7vyCCP9VgH35/lXp1zq82lwH+ztPsbZsn5p2Bkb3wuayZtH1/xFOJXgnm3ADMkTIgx7N/QUAY/hjR47iRIYtNvNUuDzhj5cKf7zdK9CsPC1zd3Edm8tiH4zZ6fFvMY9GcjjpXW+DvBV/HbxLqtyuO0PHTH90cV6Pa2h03yYbdFEbfe2RY/M9BQBy2leE20y0jt7KCKCQYLsi5P1J9frXQwJpunqB8sk3Q4YyFjVnVdRtrKH98HlI6RoOCfQ1w2q6/cRO1wlmIh0BUBQB7n/CgDa8QSXM2dyxQ2o+b95y7fh0FeYa1m6vg9uwZ4+Bcz8Rx/T1PpUWreIjqcEpnu5QinB8obIx/wI8n8K5iC60+7jN1v3xRE/vZmby0Psvf8aANXWG0yytjNcyG4lYHBZwGc+nPavJtZ1SOWWRY18qJmPyQpgH6k8n6mtXXtXtbu4ke2bYuCHuZ8bmweAvoPYVi6dpq63ehLaOWZUILu52ov+fegCjYaRLq1zst1XavLsQdq/U1o39nBpqNFG6eai7ZJSACfYela+tXKaTY/YNOnEbgYlkUghcjt6GuFeL7UxZJXMC8GR+/09aAIV8ov+5yBnhmHX8K3ING8yJX8vduGcu5BP4Vn2nlwvvSN8gYVX+83vjtUzX1yWJLopPY84oAtaJqdxb3i3MEvlyDjcDlT7MO4r0TQ7+0uVkjKLEzZM1tvyOmdyH056V4xaXr2V15qKGXGGQ9GFdvps8d5ambTpGmCEM6r8s1ufb1FAHQ6robwLI+nzPLaP8wweYz7juPf86xra8nltmsliSSQj57aVv3cw/vIeqP7VK2vSRRfvJTkDAmjyCfcjsfasq4vg+oRs7iJy2RcoPlY5/iH8zQBZku7izBt5DMbcAp5cz/PH7bu4/zxTbXWrzTblZ4J5H2nYHJ+8v8Adde/1rd1C6gms4xq0Jj3j5LqEbgxx1DVyksKRupiAmgY43IePr7dOhoA7k61YTwpMks9lK5BZV+6Pw9M/jVCHWYZJvs9+8jAMSlxEclMeqnqPY1zhgmtm8t2YKUz5NyvBGeCD6U8wIHXGRk5UnqPx/ioA7zQ55bK5kk08w3dmx+decDv8ydUPXkV6doFy13ZrHDdAIw+WORsmJvUN3GfxrxvwhewQz4Ur9pym6NiVYfTjmvV9OvNEvvLi1BY9O1I4KOwKrL7Z4zQB3ui31/DGlpql2iTjhWmQhXH+/0/OqviDTLFZ1bUXawklwFniAaPPvjp9azNL1E2byWhtZWdfmWGRjsYeqOMivQNMkstVs1WbT0IByUaMNj/AOtQB5F418OSW9qP7Y05rizx8l5YH5kH0FeX3dqqSl9LvxM0QJV03RzqB2ZD976ivqq/0GOC3c6dcSWo6+UfniP4HpXkPi21t4ZJP7VtbZFGSJlACjPfcOR+NAHkD+J7rHk3UizwglWGz5sexrPvbq3mRTZXXm5xujuLcqyf8CHBq/420iKFvtVs0ywuciRRvQj/AHhXHwwy5VvO2o2drxkjnPpQBflSWE7prYlenmQ8kfUda07C7t7uJVeS3uQOzgrIPxHPf0qncQX0cYZpzcqSOWOxx+Pf86qRzRtMoeOSObHViB39e9AHQpaPdukGnNcCZslAWDLn0J4/WtW30XxhG20WrmMEANHOOR7rmueg1XUbe4RYzcIxPyncBkex6V6/4G1HVZ44HubMXCArxICCcjsRn+VAEfgjwprc8qO8sDMxBKOgbJzz1INer2uha1ZRg22m6XM3fL7SB/jWxoN7ZG3Uy2D2r8HlNwH41ryavp8QINzGOOFPB/KgDl7TUpbaUJrK3NtJ08mOIyIfQ5BzW9HEk0TEKoR+/lOpI/Emuc8TazpWqQmBzKWjOQQSAD9aTQPEGreWIfsMd6AcKIvTtz0oAy/F+iQW0ck1vdGJ3BIXzRg/geK+ePF76ul8++eHYCdsYRTx9RX2ZbyyXMY+06XJAD1EhRh/OvO/iV4D/wCEgiZbfSIweSJI3VXGfy9PWgD5VurufygLryYwegULz27c1UtZrbG77VNEx7oOp/GvUdW+F+p2MLM8XEfRZHTJ/I1mWPgC9vgS2nygEnoVAH6UAcnABI+TFcXS+ssiDP6VXmVWmEZthFzghHB4/KvUdP8AhddBSZ7K54+6qXDDP5CtrRfBtnpVy5uLO+ck52LEG2j2PegDyGx06WdkitILt3bkAnA6/Wu10v4VeJNTMbCNIrU4J/0gRsf84r0pLnRdPbf/AGLeuw7GNVzj6DNU7n4g3EU6wab4bMPI+eR/nYeoHUUAXfCnwu1DTyUlnNuijgrMsjt7cDj8a9H0bRINNh3PBGz95pW3n9a4qz8cajbWm6SwCHk7p5gvHr3rHvvF2o6o5kuL+EQ/wxQBgB7kn60AeuyXVraQNKZ441PO4kJ+HrXI3HiS3ubiSPQ5o7ibO0ybWIU/7x/HpXkutXK36O1/dTXUQ6W9sWYvz0yKzU8ReIprf7BoGmx6ZEPl5xvC/wC0TwOKAPStc1W10GOS71TUDJdydA58wg/7CDgVwmoapf6gGultJXU/6p7xyA3uIx/WsawiurO9ae8W3vb8tkzXE7SbO/ygDr7VpXh1PUVwYZo4D/y0ICgj6Zz+dAHH3fie4ifypo7ZrgnBYKWGPQdvyqdfDE1/ZG81iaW2tRlgHAjUD1C9q6ayt5NJjzp2lWr3IB/0i7ZS34KBgVh3lprutXu+eVbls4BkbEEfvjp/M0AcpcQ6NFOHffFp6f8ALRhl5fZR1FW7rVL+50do9K09tP0pVx5rfKzr6/5zXd6T4d0TSv8AS72YapeDkPKo8tP90dK5rxh4iOo77exh2wg7WkUYA+lAHmd7GRMiM5dQctk5zz3/ABqG5vxnZEAAmRnHT6elW9SfbmBVVS3Jx1NZEqpkLnHsv9TQA+NpJOBLtXqxJqSO3ZkBVWIPfOK6TQfA9/qunW97FcaUr3Cu1rZT3qRTThSQSqN1HB646VlIXxzcqhyQVXkA+lAGBITvPXip9Ov7nT7pbmymaKdRwy+noR3FV5Pvmmj9BmgDtbfVrXWkQT7bXVeQSoAS4yO/YGhbFmleONGkmVhut/uv0zlR378UqfDjWH8NNrC3mj8Wv237D9sH2rycZ3+X24565xWHp2rTOYbe6X7SgIWIk4dOeMN6UAb9jqL2heKJxJak/vLWcEqTnrg9DUMzJbXay6Urd827HHH+y3eux174e6ha2Ut5eXmkXDoRGY4bwNc7mOAoXA3HJxg1m+KvAWs+H9IbU5bvTJo4pFSb7LdiYxMem9OqmgC/Y6xFe2jW+p2ovYcn92yhJ4fcHofw7VkT2EdpdKbK4+02jEFUOVeP2I9fcVU03UEvYR5kZ88EA4OSfQY9TT7my1FtR2nT71JCMrFNbyKWXOMj5Qcds0Ab8F5YuBBq1hIeiCdExInP613PhqxDQeSl6mraaelpefeT/dY8g1h6Jb6g8Q+1WUswx/x73EOyZT32Mww/PbrXe6GU2KrW5LYxhwEce319jQBpaPZLp8ipBLNHAT8ltdyHKH0V+fyrvdGvILeRDczS2jf3Z0wrf8CHGfyriBqlsAY7qOYW/wB12K5Kezr6e9aunag1jHG9tqEcunt/DJiSI/j1U/XigD1GKWK4jLxOkgH3sc4PvXnPxA0KRXN5Y23nRc+aFUOignksvX8q7Cxu4zEkptvlxt823bePy61oTC2vbcsQXxkZjyrjPXHegDwSfw5pt1bH7Izae/VjayAxv7FemPYiuO13w5pRWVJFBugM/ukwxHqCOGr6Ki8N2E8knm28bn+GeJtko/314/MVgax8M4rxy9rehlB3AOSjqfquP5UAfOM2k61ptsJojPd6cQMebbeYn6Zx+lbmjeGLfVIl+0W8dvngpKrKpHsT0r19Ph3rNnMJrO9XI++ElCl/rxg/lXXaJ4bhUf6XbOh/iVtsiH8etAHktj8H/Oj32NxNFGTkrG6TJ07A4IrrNC+G13pyxiPVJo2XjGxkz/MV6fFo1lCwe3tY45APvISp/MGqlxrkdlfpZTyRiZ+ERpOWHscUAc4F8QaNGNs91eRDndGyNx9DWXqnima5gZbqzknx1SWyVz+nNbfi/XYra2PNxayMCA6Mp5/HrXmWqa7pV4p+3XszOPm3vBtyfqP8aAMHXL+OS5Cx6XcW0rcK20on4jpXSeFr/XdOhVYTEDndi3A/rXJXQt7pz/YusRtJnPlSO2D/AN9ZFb2k6pJBAseo6adw4LxMNp468GgD2Xw5rOo3YRLiCZ24+aR1THHsK6VuV+fCkj+HL/0rwfTvEGmWN4gMZglY/KgcuX+nzV6T4Y1O81G6WSRgunMvCSuysD60Abt1ponSQpe3KP7RqxX6Aiudmh1uz+W1vQc/x3cQB/75ArqZtUtYpFitsSzE4IjG7B98VYjW7SAm4NrJL1yEIFAHmeo654ptZAZ7qKGJT1+zsFf9M0yPX/E15H/ocuk4PBfYcn/vqutu9OnkujLdRy3qH7scaKir+LHNZOoadbSTAnSLND0PnXRyfwBxQBxfiHQtR1N4rjVNecGMZa3tZAgf/vnmm6DptjGzyLpQjYdZpGkaRx9dvT8a7KbUjotqDDpNsqY4MUgz+RFc9qGrXmpsudP1q4LHAHmpDEP6kUAUNQ07zyJFdbaFW5K8Z+pYk/pWTdeHTfP5nlvKgGN8zFkH0X7tekaF4JnvI0lvoobSIEHyghdvzY4/St2+0HSLCDfLJCGXgvdSsw/75UigDxe5s7TTYW+1C4aNRklnEUf5Dk1zGralHcQGHTbKdgwIUR5jjPucDLV69rlxpxR/skSSkA/OtvtBP415XeXFpDqb3+q+fLJGSESIHAHpjpmgDO0HTRYzLd6tcjeWyIbeE/L9GbgfUA1u3upRSLst9PnK5/11zJ5agepZuT+AqL+3bnUrdpLCwfTbKMEG4nUbyMc7c1yUuqafHesIlNzcuebq/mLjP+ygoA0tS1FrOKR7djeSk4DAbbdPYZ5NY2jnVNQuzJdLLcQjOEDEKD7KOPzq7LcaNaKLvXZ7jUZQPkj2lVz6KvHFYmreNr3UQ9rpMP2O0xjZGME/U0AP8TaxdW48mR41I4W0t2DOf94jhfpXJXEt9KS11OsC9REnUD0JqGa9SyfJQyTdsDAHP5mqM9zNdfPcSJDEP4c5OKAGyh5ZJBEm8k5MjMMketVHEEUpDMrsOpzmluLsOvlxBlT0x96oAu3GVXJ6L/jQB634P8VeHIfCWmWutXVkq2UUkU1jc6QLiW5BZiPLmz8o+Yce1eYi6JyVMSKScLsBwM8Cq5VScyu0kp6Ig6fjVlNOuygIjVR6FsGgDJm/1pwetNBI7DNPmH7w8c0wHDd8elAHqTan4VtPh4+neH/EE2m39xZg6jCdOeSW+mAz5XnZHlx5yMAYOcnNcH9m0+PTNPuYdVJ1GSYrPai2YfZlBG19/R89doFZfpmtn+wdWs9N0fV5YRb2GozMlndPMoVnRgCTzlQDjkgUAeu654uls/Dzf2h4tvtfJuLdo4m0I2vkhZAztvYAZKgqOc1D8QfFHh7V9BlaxvtMutSuLpHtZLbRWszGgyXWSQ8OTlfX9a0fGEev2Xwzjh8Z3GtNHPfW6X1xe6lHcR3EQYn/AENUJwdvJ3A8VkfFu/0jVfh5pU2laxNdW0epSR2dsumi0hRAgDKADxt+Xk8sWOaAOf8Ah5PbaX4z07VbiN4UgaTe8Clym5GUNt64BIPHpXqenX9zJdRPb+PL/WJkjusNHG6CEugCct82dwBx90YBrxz4Sytc+M7CxnAuIHWVkt3faJZFjYomfdgBjPPSvfdIkujfW6eIvCNpo1/JBNNHbq/zSJHj5tgYnHOM55oAsSa4fs/k6tcvqVsHiCLITuUCMB2BPQlvWtm1hiu4VfTJEuo8A/ZrkbZVHse9Wry1sb2FoJrSAoD5e3lX5UHGT3rkb/wq2nSPN4fvZY/my1rdfMoPXhqANO/eO53R288lrexDaFk4Ke3POPzrh5Ztas9TEreTH/fNscFh7xng/hzRrfie6ts22tWjb0wd2zf+TZz+Fc1N4nWSJSHlSM5KvgOvXv6UAer+HfHDwOUsliklH/LKJsb/APgDYOfzrs7Lx9bzrtuLe6sbnrhkEik+6k5x9K8Hs7yy1mJotTtoZZP4JIH2N+H/ANanyay2lyC3tNTkuIkP/Hrf5LAeiv8A40AfRFt4vtpM+bDDOqnG+1b5wfXa2CPoM1tWWu2V8F8i5Uyf3ZRsYV866bqsd4glt1lSXuh559AelW/+Eilt5hGJk3/885FMbHv3yD+FAH0DNeJDKsz2bktgGWFxz9cdvrWhDdeYvzQyJ7MQf5GvnibxWyoTNM0DkdGUqvpyRkfoOlS6Z4qBO4T3TdRut23Dvg4UmgD3661CGJSCWDf7nNYN9cXOoEqi2t5COgJ8uVfcehrzd/Fs93E8MMtzcD+4+N3uOcGq0mo2lvNvna6s7h88yRMVJ9zyKANfxTJqkcXlLpl3LApxsmhWYD8c5ribqxu5AZDc3mlsvQW+GT6lSoNbd14i1O2JaFFubcjJlt2IIHXlT/SucvPENpfXJe5vr2CZeNoLKPbKsKAOS1K4uV1N4ZtTmnjH/LWKMD/x3H61Qhih84mXUYJMcYLPE34nGK7K+m0u7jRbmW9YLggrE6H8wtZSXXh5EIhkA4wfOjYk8+4oAzbjVbmzuoo7K5DWv8W5Ukb3wSM11NlrUot1c3OsGPpjyQE/8d5xXJag2iOGktby1icHpICB+IpdIuLRCGiiuJ5uMPYMen06UAes6R48XT4WWC9jRguWBD7voeKs6Z4s1vXJd9ndrBCpwRJc857YA6/nXByanfuEWBru1JOFFxEPm9siuv8ACmh6zdOrzaNYXKsDiR1cfpQB1FzqWqwRD7XqEsp/uQRK38zVOSZbsxy3Csj4wJLgRpgnrgGvQdF8KlIF+0xWFucfcgteR+JJrabw7ZmIo2cdMhEH8loA8002yWS5SRNXtpyuCVEIY/TOOK3L0FoFR7lFfsI1kdvqAK6uDw9p1id0Fg0rE5OZAP0yBWinlQoNy+SM/wCrQj+S0Ac3oml2FjCZriPU5pJCMm4Z+ueMJnitlLSyZTI9osCY4aVQp/nVv7QI4wyWzJyc7yFI9+ay7+K9mXzLTT7GSU8brhmcD8wKAMjWL3Sijxafbm8n9I/mUfjXmfiDRppC093NFZopJwJRkfQAcV2viJteMTLqAsra16KIPkzz9a8f8YPo8Cs0FqtzMDgtJIdinvkn+QoAwtVa01XU/sRF/eLGcGQP8v061n6hcW+kulvoVhZwXJ4aaZxNKB64OQtWYw8lqiqpMR/gB8qH8h8zVbtxZBsSRXFyRz5NnEIY/wAWPLfnQBzkUekySFr1dQ1vUG6xxErHn/ezmqHiP+0UtsXCw6VZfwwQEA/ifWuyvdevU3Wtjaabp6AZEZcSyY+i153rsdzqN0ftNwJ4++ABn+g/OgDk2jSRmMedgP8AD3+pNQMC7fuo8Y7k5rpZY4beNVEYlbHCoM4/GsmZ52b97shA4CJQBVIFuuXYs/ovb8ar5NxKN7Y55zwKvmJVUGQjnHL/AK8UMlsuZpMkYwqj196AJYLuC1Xbp8ZeX+KVl6U0XBbmWSUyHqd+Ky7i53rtU7VHAVelQDkZ5/OgAmP7w9ADTRkE4NPnzvOf5VGOeOfpQB13iiDT4/B/g24sbKO2uZ4Lj7TIHLNMyy7Qx9OhwO1c/pUS3OqWdtLHPNHJOkbRQHMjgsAVQHjceg962dY8c+ItZ0OPSNT1ET6cm0rF9niXG0fL8yqD+tZ8/iDU57DSrJ7gCDS2ZrPy40RomZtxO8AMTkZ5Jx2oA9f13RPDt9DptpDY6Ei/2tBahtGupnuIY23BkuQ52h224G3+IGqXxZ0PRbHwVb3EekaZpfiC3vkhuLfTZpHjiR42YJJvY5kAAz0x71w+sfEXxPq8FpFeakALWdblGgt44XMq/ddiqgsRzjPrUPivx3r/AIptI7XWLqJ7dJPOMcFtHCHk6b32gbmwcZNAFfwRo8Ot+IorS7vJLK0SOS5nniXc6JGpc7RkfNxgV3VvovgnVdRNzZ+M/Er2tvaPPO81pmeJEYBgDnBBDAgAnvntXmug6xe6FqkOoaZN5V1FkAsgdSCMFWUghgRkEGt/WvH+u6w5N1JZxRfZntBDbWccUaxuys+FUY3MVXJ68UAel+Itam8C6dbfYNbuPEdut29jdQapCUaKRFDZikByRhwOc+1PsfiVpt7B+5vZLOc/8u17l1B9mH+PevItc8TalrkbxajNE6PdPekJEF/euqq3TthRxWLn8RQB7pf+KbW7gaPUIELDsnzgj1BHT8RWSt7aImbFrW7jz80M8flyfgehry221G6twqxzExj+BuQK3LDxFDvUXMOw9dzYZfx74oA6hrjSNzPD59uwIZoWIAHbIamXOoW8qqn2lbmMjhLpORjsrjkfXNURd6fqBDRAI+ODH8wP/Aeoq9pVrYGZVvBHAucBiTGjfj0/CgAs57HcFF/cadN2Ep3p+DDkVtfabsW4jl1e2uIMZUSrvH8q1f8AhELaa1WRC0aE7gxRZUOf9pePfp3rltS8OyQSM0CJJGCBvtDuX8VzkUAV4724sZ9rXjtG3IMJyv5Hinxaw1tchlg3E5zLH+7f8SOKrraNaEMNzbRzHJGcH3wauvc6Rcw7Vk/s+4zyWG+In6daAOm/ti8v7MFQG4wRcwgnp2dfxrDnk1WGJis1zEuM+U5Lx4z0yc1lWt/eWxaO28wJnIMZAVvcZq1JctLARdPdQuwPzCXAb/gJ4oApy3U4kYyCSBgefJBA/IcVXuNTaQFHKzkcnzVIoUZmco96Tu7LnAx9cetWmubmCIFNSYKMfLcQL/OgDEl1S4jIA89FHIRbhtp/Wp7XWC67jBECM8tuYmrMt/53EyW8ozgFUXnpVZpZ4ph9nOwE5+RMqfzoAnfVPPkJkS3CZHIiyfw4rsPC+t28arHvk56bUwD+QFcfGJZnBk8mT1AjGevfFXbKzmjuPtAEDRHny3UlSKAPSP7SlEqG0muXywyDan5R7EV7T4F1KNIlW51a6R8Z2OCcj8RXz1onidbSby4ks7ZR1ZYnP48NXtfgxkuFWWbVkAK5wLQAg5/2jQB6y9wRZu9ozTyYygI6n9Kp28t5NEPt9tdLJ3WLaEP65o06+jlxGs9y5zgExgD9Kt3li1wu3zj5ZGGQ5+b8QeKAMW/me2YC2sb2a4kz8jXC4U/TJOPwpttYazfyZvJ7i0hz/q43AAHpkcmrpspLCUSWGk2ksh43+eVb9Vq5Zz6pJzdWUEIPZZ939KAKc2kaVbuJLqaUsOheds5HsDzUGp6ibO2I02F2zz5suTjntuNat3e2VgfMvJLaBvVnG4/Tua58a1faldslvpiQ2Y4FxKu4t9FIFAHm2uQaxqtw8pt57k9CzN8o5rnr7wlq00ZkmVoo15ysYbb+LV7VqU/2aLzJ5Lm4YHjfKqIPz4rj9W1iGaNjJHPcgD7sILgfVjgUAeKanp0dvchLq8uyWOArOBu9gorPuJbIoI5L/wCzwKcYD7nJ9D2rovGGsT3ErwWNrZ6eMkFmkWWZh7KoOK52x0y5dT5WmW8agfNdXYAGPUDk0AUZLnRoIm+xrNeNnhQCQffgAfia5yee4lkMrwkKOBEgCov5de9dXcXGn2p2XV6tzITgRQJtU+wUck1lazqm2GRJbODT4lAJ+2zbZCMZGIl+Y57UAcpdXs7MEwkK9z6H6Cq8zxRxuVMtw4GdwAVB9arXWrRbj9ni3sOjsMD646/nWXc3M1z/AK6V3HZc4A/CgAnuSZixILE+vSoJJWc/MxPtmmk5OeKQ96AE46VIpGP/AK1M7/jUqZ2igAlBLnA/WmD2p0rf6QRgijHPTNACfUGk9KdjOOKAvPAoAB16UuMduaB9KD+tAAOtO5AHBpB06cfSnBSAQB1/SgBwJG7GeeDijuMjH1puDxnmnAHpzQAuPb0pRxnFJjHbinbW7jp70AKjFHDoWRx0IPNbFn4m1O3IDyrcR55SVAQaxwCexxRj16elAHpXh/x7pdqoElpe6dNgZks3+Qn1K5x+GKuXnieyv5DLbuk85GRMn7iUdhuwea8pwfQkDinFcnkDHYelAHplrr9ykpSR7uL5jtfqD+YP8hUWpTX0iF1S1uV4+cRhW56dOtcHb6hewACKeQDPQ8g/nVu3129h43ZU8ELxx7UAb1tHcqXaKaKJjyVBH8jTb+4u1TEsUbKM/PETgfUdKy31i1u8m8gmLc4C4OfyxSLd2KMGtnuYz7sf/wBVAFyw1RogWhePce+Dke3NdDpKx6qSbrVbS3xjCyQkg/jnpWDp2ows4SQLJ0+8B/Oupg8qW2YDTHmGfvwqsh9+M0AXpvDdp5Rxe6BcAn7yyNG3+Fc5d2+n2LnzBZlV/wCec5cim3ywDcD5kSnkLLalefrXNXarHMZFWNgO+T/hQBsFrC5IESTR7ujgjGfWrcFrAy7TrIhPTMoJyPwrDia4eMmPYFPPCkn8u9RGOZWJnjZhn7wX+lAHaeHrbSzfhbuaSfnG+BxDn33Fq+iPAvh3w08UZ828Y4J+e63Z96+XvD8lrHeh57eCZRjh8pn3yK+gPA+racLeLy9PsQoHCecxx+tAHt1toOlwRoIfMQDp+/b/ABqC81hdNxFa2t1dk8L5MJfA+ueayYNct44lENlaKT7Mw/lWnaalqNz8yLlM8KkYTH4saAK15eapfxFRaahChH3UUIfzIJ/KuU1rT57TarS3tuZOVWSYtn68ius1HWNYU+VDFZWrHjdc3aZ+u0ZNcNrI025M1z4k8Z6Qhgy8kcUq5jx2POSc9sUAaOjaRJbx+Zc6pG8jdRAAhP48tVq/u9TtOYBFGByZHBkf83P9K89l8feAtCkWODxBJdAruD2ts8gHsSMc8VyPiL406VcPEtlpurTwH/WGSSO3bPoPvZ+tAHp41trnLXE0zyITy6ByP6VxnjTXJ7wfYrL7VO0gKmQsqRx/U9PwrxrUfH+pyLItnawWZcsWfe8rMCePvHAI9QK5jV9b1PVOL67nkXAymQq8dPlGBn3xmgD1VDpXh/M+r+INNE6ZJhtl82UkdR9fyrnvEvxA0y7DQWsWoXUIJ5dhCjccdMkjPUce1eaEYOVXk/rTcHPv9aANOXX78Ai0ZLJS2f8ARl2uOcgb/vfrWTI7PIzyMWduWZjkk+uTSkH0pMc9CfpQAzvwB+VIeAc4/wAaftPbOKbt9jQAxunQf1pCOvA/GpAp9OQaQqfTNADD16AVKg+XtTCv86kUECgD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique view showing the three horns of the lateral ventricles, which are dilated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35066=[""].join("\n");
var outline_f34_15_35066=null;
var title_f34_15_35067="Acute versus chronic DIC";
var content_f34_15_35067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Coagulation parameters in acute and chronic disseminated intravascular coagulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute (decompensated) DIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic (compensated) DIC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet count",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin time",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activated partial thromboplastin time",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombin time",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma fibrinogen",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Normal-elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma factor V",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma factor VIII",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrin degradation products",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D-dimer",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35067=[""].join("\n");
var outline_f34_15_35067=null;
var title_f34_15_35068="Spinal cord sensory levels";
var content_f34_15_35068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensory loss in patients with spinal cord disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"1\">",
"        Area of sensory loss",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Cervical spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supraclavicular fossa",
"       </td>",
"       <td>",
"        C3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Top of acromioclavicular point",
"       </td>",
"       <td>",
"        C4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lateral antecubital fossa",
"       </td>",
"       <td>",
"        C5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thumb",
"       </td>",
"       <td>",
"        C6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Middle finger",
"       </td>",
"       <td>",
"        C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Little finger",
"       </td>",
"       <td>",
"        C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Thoracic spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ulnar side of antecubital fossa",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apex of axilla",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fourth intercostal space (nipple line)",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tenth intercostal space (umbilicus)",
"       </td>",
"       <td>",
"        T10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Midpoint of inguinal ligament",
"       </td>",
"       <td>",
"        T12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Lumbar spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Halfway between T12 and L2",
"       </td>",
"       <td>",
"        L1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mid-anterior thigh",
"       </td>",
"       <td>",
"        L2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medial femoral condyle",
"       </td>",
"       <td>",
"        L3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medial malleolus",
"       </td>",
"       <td>",
"        L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dorsum of third metatarsophalangeal joint",
"       </td>",
"       <td>",
"        L5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Sacral spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lateral heel",
"       </td>",
"       <td>",
"        S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Midline popliteal fossa",
"       </td>",
"       <td>",
"        S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ischial tuberosity",
"       </td>",
"       <td>",
"        S3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perianal",
"       </td>",
"       <td>",
"        S4-5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from McGee, S, Evidence-Based Physical Diagnosis, WB Saunders Company, 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35068=[""].join("\n");
var outline_f34_15_35068=null;
var title_f34_15_35069="Survival CHD LVEF";
var content_f34_15_35069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival in coronary heart disease is related to left ventricular ejection fraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival analysis during medical therapy of 23,467 patients enrolled in the CASS trial who had one, two, or three vessel disease shows that the overall 12-year survival is related to the left ventricular ejection fraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Emond M, Mock MB, Davis KB, et al. Circulation 1994; 90:2645.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35069=[""].join("\n");
var outline_f34_15_35069=null;
var title_f34_15_35070="Rx pseudoobstruction ASGE";
var content_f34_15_35070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute colonic dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 651px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisen GM, Baron TH, Dominitz JA, et al. Acute colonic pseudo-obstruction. Gastrointest Endosc 2002; 56:789. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35070=[""].join("\n");
var outline_f34_15_35070=null;
var title_f34_15_35071="Agenesis lower vagina complete";
var content_f34_15_35071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Agenesis (atresia) of the lower vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_15_35071=[""].join("\n");
var outline_f34_15_35071=null;
